<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Growth factors for treating diabetic foot ulcers - Martí‐Carvajal, AJ - 2015 | Cochrane Library</title> <meta content="Growth factors for treating diabetic foot ulcers - Martí‐Carvajal, AJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Growth factors for treating diabetic foot ulcers - Martí‐Carvajal, AJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008548.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Growth factors for treating diabetic foot ulcers" name="citation_title"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Susana Nicola" name="citation_author"/> <meta content="Universidad Tecnológica Equinoccial" name="citation_author_institution"/> <meta content="Daniel Simancas‐Racines" name="citation_author"/> <meta content="Universidad Tecnológica Equinoccial" name="citation_author_institution"/> <meta content="Ludovic Reveiz" name="citation_author"/> <meta content="Patricio Oliva" name="citation_author"/> <meta content="Universidad del Desarrollo" name="citation_author_institution"/> <meta content="Jorge Cedeño‐Taborda" name="citation_author"/> <meta content="Centro de Investigación UNILIME / Universidad de Carabobo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD008548.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amputation, Surgical; Diabetes Mellitus, Type 1 [*complications]; Diabetes Mellitus, Type 2 [*complications]; Diabetic Foot [*therapy]; Growth Substances [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Wound Healing" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008548.pub2&amp;doi=10.1002/14651858.CD008548.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008548\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008548\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008548.pub2",title:"Growth factors for treating diabetic foot ulcers",firstPublishedDate:"Oct 28, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008548.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008548.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008548.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008548.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008548.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008548.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008548.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9193 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008548.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/appendices#CD008548-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/table_n/CD008548StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/table_n/CD008548StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Growth factors for treating diabetic foot ulcers</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0003">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0004">Susana Nicola</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0005">Daniel Simancas‐Racines</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0006">Ludovic Reveiz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0007">Patricio Oliva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information#CD008548-cr-0008">Jorge Cedeño‐Taborda</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information/en#CD008548-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008548.pub2">https://doi.org/10.1002/14651858.CD008548.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008548-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008548-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008548-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008548-abs-0001" lang="en"> <section id="CD008548-sec-0001"> <h3 class="title" id="CD008548-sec-0001">Background</h3> <p>Foot ulcers are a major complication of diabetes mellitus, often leading to amputation. Growth factors derived from blood platelets, endothelium, or macrophages could potentially be an important treatment for these wounds but they may also confer risks. </p> </section> <section id="CD008548-sec-0002"> <h3 class="title" id="CD008548-sec-0002">Objectives</h3> <p>To assess the benefits and harms of growth factors for foot ulcers in patients with type 1 or type 2 diabetes mellitus. </p> </section> <section id="CD008548-sec-0003"> <h3 class="title" id="CD008548-sec-0003">Search methods</h3> <p>In March 2015 we searched the Cochrane Wounds Group Specialised Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library)</i>, Ovid MEDLINE, Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations, Ovid EMBASE and EBSCO CINAHL. There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD008548-sec-0004"> <h3 class="title" id="CD008548-sec-0004">Selection criteria</h3> <p>Randomised clinical trials in any setting, recruiting people with type 1 or type 2 diabetes mellitus diagnosed with a foot ulcer. Trials were eligible for inclusion if they compared a growth factor plus standard care (e.g., antibiotic therapy, debridement, wound dressings) versus placebo or no growth factor plus standard care, or compared different growth factors against each other. We considered lower limb amputation (minimum of one toe), complete healing of the foot ulcer, and time to complete healing of the diabetic foot ulcer as the primary outcomes. </p> </section> <section id="CD008548-sec-0005"> <h3 class="title" id="CD008548-sec-0005">Data collection and analysis</h3> <p>Independently, we selected randomised clinical trials, assessed risk of bias, and extracted data in duplicate. We estimated risk ratios (RR) for dichotomous outcomes. We measured statistical heterogeneity using the I<sup>2</sup> statistic. We subjected our analyses to both fixed‐effect and random‐effects model analyses. </p> </section> <section id="CD008548-sec-0006"> <h3 class="title" id="CD008548-sec-0006">Main results</h3> <p>We identified 28 randomised clinical trials involving 2365 participants. The cause of foot ulcer (neurologic, vascular, or combined) was poorly defined in all trials. The trials were conducted in ten countries. The trials assessed 11 growth factors in 30 comparisons: platelet‐derived wound healing formula, autologous growth factor, allogeneic platelet‐derived growth factor, transforming growth factor β2, arginine‐glycine‐aspartic acid peptide matrix, recombinant human platelet‐derived growth factor (becaplermin), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human vascular endothelial growth factor, recombinant human lactoferrin, and recombinant human acidic fibroblast growth factor. Topical intervention was the most frequent route of administration. All the trials were underpowered and had a high risk of bias. Pharmaceutical industry sponsored 50% of the trials. </p> <p>Any growth factor compared with placebo or no growth factor increased the number of participants with complete wound healing (345/657 (52.51%) versus 167/482 (34.64%); RR 1.51, 95% CI 1.31 to 1.73; I<sup>2</sup> = 51%, 12 trials; <i>low quality evidence</i>). The result is mainly based on platelet‐derived wound healing formula (36/56 (64.28%) versus 7/27 (25.92%); RR 2.45, 95% 1.27 to 4.74; I<sup>2</sup> = 0%, two trials), and recombinant human platelet‐derived growth factor (becaplermin) (205/428 (47.89%) versus 109/335 (32.53%); RR 1.47, 95% CI 1.23 to 1.76, I<sup>2</sup>= 74%, five trials). </p> <p>In terms of lower limb amputation (minimum of one toe), there was no clear evidence of a difference between any growth factor and placebo or no growth factor (19/150 (12.66%) versus 12/69 (17.39%); RR 0.74, 95% CI 0.39 to 1.39; I<sup>2</sup> = 0%, two trials; very <i>low quality evidence</i> ). One trial involving 55 participants showed no clear evidence of a difference between recombinant human vascular endothelial growth factor and placebo in terms of ulcer‐free days following treatment for diabetic foot ulcers (RR 0.64, 95% CI 0.14 to 2.94; P value 0.56, <i>low quality of evidence</i>) </p> <p>Although 11 trials reported time to complete healing of the foot ulcers in people with diabetes , meta‐analysis was not possible for this outcome due to the unique comparisons within each trial, failure to report data, and high number of withdrawals. Data on quality of life were not reported. Growth factors showed an increasing risk of overall adverse event rate compared with compared with placebo or no growth factor (255/498 (51.20%) versus 169/332 (50.90%); RR 0.83; 95% CI 0.72 to 0.96; I<sup>2</sup> = 48%; eight trials; <i>low quality evidence</i>). Overall, safety data were poorly reported and adverse events may have been underestimated. </p> </section> <section id="CD008548-sec-0007"> <h3 class="title" id="CD008548-sec-0007">Authors' conclusions</h3> <p>This Cochrane systematic review analysed a heterogeneous group of trials that assessed 11 different growth factors for diabetic foot ulcers. We found evidence suggesting that growth factors may increase the likelihood that people will have complete healing of foot ulcers in people with diabetes. However, this conclusion is based on randomised clinical trials with high risk of systematic errors (bias). Assessment of the quality of the available evidence (GRADE) showed that further trials investigating the effect of growth factors are needed before firm conclusions can be drawn. The safety profiles of the growth factors are unclear. Future trials should be conducted according to SPIRIT statement and reported according to the CONSORT statement by independent investigators and using the Foundation of Patient‐Centered Outcomes Research recommendations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008548-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008548-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008548-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008548-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008548-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008548-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008548-abs-0004" lang="en"> <h3>Growth factors for treating diabetic foot ulcers</h3> <p><b>What are diabetic foot ulcers?</b> </p> <p>People who suffer from diabetes mellitus (usually referred to as ‘diabetes’) can develop wounds (ulcers) on their feet and ankles. These diabetic foot ulcers can take a long time to heal, and affect quality of life for people with diabetes. In some people, failure of these ulcers to heal can contribute to the need for some level of amputation on the foot. Any treatments that encourage diabetic foot ulcers to heal will be valuable. </p> <p><b>What are growth factors?</b> </p> <p>Growth factors are substances that occur naturally in the body. They promote growth of new cells and healing of wounds. Treatment of diabetic foot ulcers with growth factors may improve the healing of ulcers. </p> <p><b>The purpose of this review</b> </p> <p>This Cochrane review tried to identify the benefits and harms of treating diabetic foot ulcers with growth factors in addition to providing standard care (i.e. pressure relief, removal of dead tissue from the wound, infection control and application of dressings). </p> <p><b>Findings of this review</b> </p> <p>The review authors searched the medical literature up to 3 March 2015, and identified 28 relevant medical trials, with a total of 2365 participants. The trials were performed in ten different countries, generally in out‐patient settings. All the trials had low numbers of participants, which makes potential overestimation of benefits and underestimation of harms more likely. Half of the trials were sponsored by the pharmaceutical industry that produces these growth factors. </p> <p>The trials tested 11 different types of growth factor, usually by applying them to the ulcer surface. Growth factors had no effect on the risk of having one toe or more amputated when compared with either another growth factor, or placebo (inactive fake medicine), or standard care alone (evidence from four trials). However, when compared with placebo or no growth factor, growth factors seemed to make complete healing of ulcers (wound closure) more likely to occur (evidence from 12 trials). </p> <p><b>Shortcomings of the trials included in this review</b> </p> <p>None of the trials reported data on participants’ quality of life. Harms caused by treatments were poorly reported, so the safety profile of growth factors remains unclear. </p> <p>It is clear that more trials are required to assess the benefits and harms of growth factors in the treatment of diabetic foot ulcers. These trials should be well‐designed, conducted by independent researchers (not industry‐sponsored), and have large numbers of participants. They should report outcomes that are of interest to patients, such as: how many of the participants’ ulcers healed, and how long the healing took; any level of amputation in the foot; quality of life; ulcer‐free days following treatment; and harms caused by treatment, including whether there are any potential cancer risks. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008548-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-sec-0097">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-sec-0155">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008548-sec-0097"></div> <h3 class="title" id="CD008548-sec-0098">Implications for practice</h3> <section id="CD008548-sec-0098"> <p>There is insufficient evidence from RCTs to recommend or refute the use of growth factors in treating diabetic foot ulcers. The results are based on the results of 28 RCTs with a high risk of bias. There is a paucity of information for other main clinical outcomes such as lower limb amputation, time to complete healing of the diabetic foot ulcer and ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence). There is an absence of information on mortality, and quality of life. In addition, adverse events data remain unclear. Therefore, prescription of growth factors for treating people with diabetic foot ulcers can not be supported or rejected until new evidence from a large, high‐quality trial becomes available and alters this conclusion. </p> </section> <h3 class="title" id="CD008548-sec-0099">Implications for research</h3> <section id="CD008548-sec-0099"> <p>This systematic review has identified the need for well‐designed, adequately powered RCTs to assess the benefits and harms of growth factors with complete wound closure, lower limb amputation, and adverse events as the primary outcomes. Since epidemiological studies have connected to the recombinant human platelet‐derived growth factor (becaplermin) to a five‐fold increase in cancer mortality in people who used more than three tubes of it compared to non‐users, potential risk needs to be ruled out in large randomised clinical trials before wider use can be recommended. The trials should be designed according to the SPIRIT statement (<a href="./references#CD008548-bbs2-0069" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586. ">Chan 2013</a>), and reported according to the CONSORT statement for improving the quality of reporting of efficacy; the trials should also provide better reports of harms/adverse events encountered during their conduct (<a href="./references#CD008548-bbs2-0103" title="IoannidisJP , EvansSJ , GotzschePC , O'NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781‐8. ">Ioannidis 2004</a>; <a href="./references#CD008548-bbs2-0127" title="MoherD , HopewellS , SchulzKF , MontoriV , GotzschePC , DevereauxPJ . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869. ">Moher 2010</a>; <a href="./references#CD008548-bbs2-0151" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology2010;63(8):834‐40. ">Schulz 2010</a>). Future trials should be planned following the Foundation of Patient‐Centered Outcomes Research recommendations (<a href="./references#CD008548-bbs2-0060" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636‐40. ">Basch 2012</a>; <a href="./references#CD008548-bbs2-0078" title="GabrielSE , NormandSL . Getting the methods right ‐ the foundation of patient‐centered outcomes research. The New England Journal of Medicine2012;367(9):787‐90. ">Gabriel 2012</a>; <a href="./references#CD008548-bbs2-0124" title="McKinneyM . 'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding. Modern Healthcare2012; Vol. 42, issue 5:12‐3. ">McKinney 2012</a>). Potential trials should also include clinical outcomes such as, incidence of lower limb amputation (minimum of one toe, with the extent of amputation being specified, and data the incidence of different extents of amputation also reported separately), time to complete healing of the diabetic foot ulcer, quality of life, ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence), and adverse events. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008548-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008548-sec-0022"></div> <div class="table" id="CD008548-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> foot ulcers in people with diabetes<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> any growth factor<br/> <b>Comparison:</b> placebo or no growth factor </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Any growth factor</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete wound closure</b> <br/> Follow‐up: 4 to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>523 per 1000</b> <br/> (454 to 599) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.51</b> <br/> (1.31 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1316<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.‐ Growth factors investigated included autologous growth factor (1 trial); platelet‐derived wound healing formula (2 trials); recombinant human platelet‐derived growth factor (becaplermin) (5 trials), recombinant human basic fibroblast growth factor (2 trials), recombinant human epidermal growth factor (1 trial), and transforming growth factor (1 trial). </p> <p>2.‐ Trials differed in quality.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower limb amputation (minimum of one toe)</b> <br/> Follow‐up: 8 to 20 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> <br/> (64 to 235) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.39 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelet‐derived wound healing formula (1 trial), and recombinant human epidermal growth factor (1 trial) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial authors reported recurrence of ulcer in 27% (4/15) of participants receiving growth factor (recombinant human vascular endothelial growth factor) versus 33% (3/9) in placebo group. Hazard ratio was calculated using data transformation. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete healing of the diabetic foot ulcer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not possible due to the unique comparisons within each trial, failure to report data, with or without a high rate of withdrawals. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials assessed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (non‐serious and serious)</b> <br/> Follow‐up: 5 to 20 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>404 per 1000</b> <br/> (325 to 502) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.79 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recombinant human epidermal growth factor (1 trial), recombinant human platelet‐derived growth factor (1 trial), recombinant human vascular endothelial growth factor (1 trial), thrombin‐induced, platelet‐released platelet‐derived wound healing formula (1 trial). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk is based on the risks for the control group in the meta‐analysis.<br/> <sup>2</sup> Downgraded one level for limitations in design and execution: Eleven out thirteen trials assessing this outcome have high risk for selection bias. And outcome assessment was performed in unclear fashion.<br/> <sup>3</sup> Downgraded one level for inconsistency (I<sup>2</sup>: 51%).<br/> <sup>4</sup> Downgraded one level for limitations in design and execution.<br/> <sup>5</sup> Downgraded two levels for imprecision: small sample size and very low rate of events conducting to wide confidence intervals.<br/> <sup>6</sup> Downgraded one level for imprecision: Low rate of adverse events resulting in wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008548-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-sec-0131">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD008548-sec-0023"></div> <p>See <a href="./appendices#CD008548-sec-0103">Appendix 1</a> for medical and epidemiological terms. </p> <section id="CD008548-sec-0024"> <h3 class="title" id="CD008548-sec-0024">Description of the condition</h3> <p>It is estimated that in 2011, approximately 366 million people had diabetes, that is 7.0% of the world’s population (<a href="./references#CD008548-bbs2-0055" title="BakkerK , SchaperNC . The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):116‐8. ">Bakker 2012a</a>). Around 80% of these people live in low‐ or middle‐income countries. By 2030, the global estimate is expected to rise to 552 million – that is 8.3% of the adult population (<a href="./references#CD008548-bbs2-0055" title="BakkerK , SchaperNC . The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):116‐8. ">Bakker 2012a</a>). The development of foot ulcers is a major complication of diabetes mellitus (<a href="./references#CD008548-bbs2-0064" title="BoultonAJ , VileikyteL , Ragnarson‐TennvallG , ApelqvistJ . The global burden of diabetic foot disease. Lancet2005;366:1719‐24. ">Boulton 2005</a>; <a href="./references#CD008548-bbs2-0123" title="LipskyBA , BerendtAR , DeeryHG , EmbilJM , JosephWS , KarchmerAW , Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clinical Infectious Disease2004;39:885‐910. ">Lipsky 2004</a>; <a href="./references#CD008548-bbs2-0142" title="RathurHM , BoultonAJ . The diabetic foot. Clinics in Dermatology2007;25:109‐20. ">Rathur 2007</a>; <a href="./references#CD008548-bbs2-0145" title="RichardJL , SchuldinerS . Epidemiology of diabetic foot problems [Épidémiologie du pied diabétique]. La Revue Médicine Interne2008;29(Suppl 2):222‐30. ">Richard 2008</a>; <a href="./references#CD008548-bbs2-0154" title="SibbaldRG , WooKY . The biology of chronic foot ulcers in persons with diabetes. Diabetes/Metabolism Research and Reviews2008;24(Suppl 1):25‐30. ">Sibbald 2008</a>). The International Working Group on the Diabetic Foot defines a foot ulcer as a full thickness wound involving the foot or ankle (<a href="./references#CD008548-bbs2-0117" title="LaveryLA , PetersEJ , WilliamsJR , MurdochDP , HudsonA , LaveryDC , International Working Group on the Diabetic Foot. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care2008;31:154‐6. ">Lavery 2008</a>), that is, "a wound penetrating through the dermis" (<a href="./references#CD008548-bbs2-0148" title="SchaperNC . Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews2004;20(Suppl 1):90‐5. ">Schaper 2004</a>). A wound is a break in the epithelial integrity of the skin and may be accompanied by disruption of the structure and function of underlying normal tissue (<a href="./references#CD008548-bbs2-0074" title="EnochS , LeaperDJ . Basic science of wound healing. Surgery2008;26(2):31‐7. ">Enoch 2008</a>). </p> <section id="CD008548-sec-0025"> <h4 class="title">Epidemiology of the foot ulcer in people with diabetes</h4> <p>The proportion of diabetic foot ulcers among people with diabetes mellitus varies across studies, ranging from 5% to 43% (<a href="./appendices#CD008548-sec-0104">Appendix 2</a>). There are four classification systems for diabetic foot ulcers that are summarised in <a href="./appendices#CD008548-sec-0105">Appendix 3</a> (<a href="./references#CD008548-bbs2-0102" title="InceP , AbbasZG , LutaleJK , BasitA , AliSM , ChohanF , et al. Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents. Diabetes Care2008;31:964‐7. ">Ince 2008</a>; <a href="./references#CD008548-bbs2-0116" title="LaveryLA , ArmstrongDG , HarklessLB . Classification of diabetic foot wounds. The Journal of Foot and Ankle Surgery1996;35:528‐31. ">Lavery 1996</a>; <a href="./references#CD008548-bbs2-0148" title="SchaperNC . Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews2004;20(Suppl 1):90‐5. ">Schaper 2004</a>; <a href="./references#CD008548-bbs2-0168" title="WagnerFW . The dysvascular foot: a system of diagnosis and treatment. Foot and Ankle International1981;2:64‐122. ">Wagner 1981</a>). Outcomes for diabetic foot ulcers are predicted by ulcer area, presence of peripheral arterial disease, duration of diabetes, and presence of osteomyelitis (infection of bone) (<a href="./references#CD008548-bbs2-0101" title="InceP , KendrickD , GameF , JeffcoateW . The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes. Diabetic Medicine2007;24:977‐81. ">Ince 2007</a>; <a href="./references#CD008548-bbs2-0118" title="LaveryLA , PetersEJ , ArmstrongDG , WendelCS , MurdochDP , LipskyBA . Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Research and Clinical Practice2009;83:347‐52. ">Lavery 2009</a>; <a href="./references#CD008548-bbs2-0132" title="OyiboSO , JudeEB , TarawnehI , NguyenHC , ArmstrongDG , HarklessLB . The effects of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabetic Medicine2001;18:133‐8. ">Oyibo 2001</a>). </p> <p>There is a close relationship between the presence of a diabetic foot ulcer and the amputation of a toe or a lower limb (<a href="./references#CD008548-bbs2-0065" title="BoultonAJ . The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews2008;24 (Suppl 1):3‐6. ">Boulton 2008</a>; <a href="./references#CD008548-bbs2-0056" title="BakkerK , ApelqvistJ , SchaperNC . Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):225‐31. ">Bakker 2012b</a>; <a href="./references#CD008548-bbs2-0173" title="YounesNA , AlbsoulAM , AwadH . Diabetic heel ulcers: a major risk factor for lower extremity amputation. Ostomy/Wound Management2004;50:50‐60. ">Younes 2004</a>). Indeed, <a href="./references#CD008548-bbs2-0065" title="BoultonAJ . The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews2008;24 (Suppl 1):3‐6. ">Boulton 2008</a> and <a href="./references#CD008548-bbs2-0055" title="BakkerK , SchaperNC . The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):116‐8. ">Bakker 2012a</a> reported that more than 85% of such amputations were preceded by an active foot ulcer. Amputation is a major complication for people with a diabetic foot ulcer (<a href="./references#CD008548-bbs2-0059" title="BartusCL , MargolisDJ . Reducing the incidence of foot ulceration and amputation in diabetes. Current Diabetes Reports2004;4:413‐8. ">Bartus 2004</a>; <a href="./references#CD008548-bbs2-0149" title="SchaperNC , ApelqvistJ , BakkerK . Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia2012;55(7):1869‐72. ">Schaper 2012a</a>), and is a risk factor for increased mortality (<a href="./references#CD008548-bbs2-0106" title="IzumiY , SatterfieldK , LeeS , HarklessLB , LaveryLA . Mortality of first‐time amputees in diabetics: a 10‐year observation. Diabetes Research and Clinical Practice2009;83(1):126‐31. ">Izumi 2009</a>). The incidence of amputations is higher in people with diabetes (range 0.64 to 5.25 per 1000 person‐years) than in people without diabetes (0.03 to 0.24 per 1000 person‐years) (<a href="./references#CD008548-bbs2-0149" title="SchaperNC , ApelqvistJ , BakkerK . Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia2012;55(7):1869‐72. ">Schaper 2012a</a>). The reported annual incidence of major amputation in industrialised countries ranges from 0.06 to 3.83 per 1000 diabetic people (<a href="./references#CD008548-bbs2-0109" title="JeffcoateWJ . The incidence of amputation in diabetes. Acta Chirurgica Belgica2005;105:140‐2. ">Jeffcoate 2005</a>). The incidence varies between countries, races, and communities (<a href="./references#CD008548-bbs2-0109" title="JeffcoateWJ . The incidence of amputation in diabetes. Acta Chirurgica Belgica2005;105:140‐2. ">Jeffcoate 2005</a>), however, there is concern about the methods used to calculate incidence and prevalence of amputation in people with diabetes (<a href="./references#CD008548-bbs2-0164" title="VanHoutumWH . Amputations and ulceration; pitfalls in assessing incidence. Diabetes/Metabolism Research and Reviews2008;24(Suppl 1):14‐8. ">Van Houtum 2008</a>). The incidence of reamputation in diabetic people with history of amputation within two years is almost 50% (<a href="./references#CD008548-bbs2-0110" title="KanadeR , VanDeursenR , BurtonJ , DaviesV , HardingK , PriceP . Re‐amputation occurrence in the diabetic population in South Wales, UK. International Wound Journal2007;4:344‐52. ">Kanade 2007</a>). Reamputation could be due to poor selection of the original amputation level through efforts to save as much of the lower extremity as possible (<a href="./references#CD008548-bbs2-0157" title="SkoutasD , PapanasN , GeorgiadisGS , ZervasV , ManesC , MaltezosE , et al. Risk factors for ipsilateral reamputation in patients with diabetic foot lesions. The International Journal of Lower Extremity Wounds2009;8:69‐74. ">Skoutas 2009</a>). </p> </section> <section id="CD008548-sec-0026"> <h4 class="title">Diabetic foot ulcer pathways</h4> <p>The commonest causes of foot ulcers in people with diabetes are peripheral neuropathy (nerve damage), foot deformity, external trauma, peripheral vascular disease, and peripheral oedema (<a href="./references#CD008548-bbs2-0065" title="BoultonAJ . The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews2008;24 (Suppl 1):3‐6. ">Boulton 2008</a>; <a href="./references#CD008548-bbs2-0076" title="Figueroa‐RomeroC , SadidiM , FeldmanEL . Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Reviews in Endocrine &amp; Metabolic Disorders2008;9:301‐14. ">Figueroa‐Romero 2008</a>; <a href="./references#CD008548-bbs2-0140" title="QuattriniC , JeziorskaM , BoultonAJ , MalikRA . Reduced vascular endothelial growth factor expression and intra‐epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care2008;31:140‐5. ">Quattrini 2008</a>; <a href="./references#CD008548-bbs2-0150" title="SchaperNC , AndrosG , ApelqvistJ , BakkerK , LammerJ , LepantaloM , et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes/Metabolism Research and Reviews2012;28(Suppl 1):218‐24. ">Schaper 2012b</a>; <a href="./references#CD008548-bbs2-0161" title="SzaboC . Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. British Journal of Pharmacology2009;156:713‐27. ">Szabo 2009</a>). Other significant risk factors include being over 75 years of age, use of insulin, poor psychosocial status, hyperkeratosis (thickening of the outermost layer of skin), macrovascular and microvascular complications, and duration of diabetes (<a href="./references#CD008548-bbs2-0070" title="ChaoCY , CheingGL . Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes/Metabolism Research and Reviews2009;25:604‐14. ">Chao 2009</a>; <a href="./references#CD008548-bbs2-0105" title="IversenMM , MidthjellK , ØstbyeT , TellGS , ClippE , SloaneR , et al. History of and factors associated with diabetic foot ulcers in Norway: the Nord‐Trøndelag Health Study. Scandinavian Journal of Public Health2008;36:62‐8. ">Iversen 2008</a>; <a href="./references#CD008548-bbs2-0122" title="LeymarieF , RichardJL , MalgrangeD . Factors associated with diabetic patients at high risk for foot ulceration. Diabetes and Metabolism2005;31:603‐5. ">Leymarie 2005</a>). </p> </section> </section> <section id="CD008548-sec-0027"> <h3 class="title" id="CD008548-sec-0027">Description of the intervention</h3> <p>Many studies have experimented with biological agents, aiming to modify the pathophysiology of diabetic foot ulcers. Growth factors are examples of these biological agents, and are considered to be a potentially important technological advance in the area of wound healing (<a href="./references#CD008548-bbs2-0133" title="PapanasN , MaltezosE . Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?. The International Journal of Lower Extremity Wounds2007;6:37‐53. ">Papanas 2007</a>).<br/> <br/> Growth factors are platelet‐derived, endothelium‐derived, or macrophage‐derived, and include granulocyte colony‐stimulating factor, platelet‐derived growth factor, epidermal growth factor, transforming growth factor, fibroblast growth factor, vascular endothelial growth factor, insulin‐like growth factor, and keratinocyte growth factor (<a href="./references#CD008548-bbs2-0051" title="AmeryCM . Growth factors and the management of the diabetic foot. Diabetic Medicine2005;22 Suppl 1:12‐4. ">Amery 2005</a>; <a href="./references#CD008548-bbs2-0058" title="BarrientosS , StojadinovicO , GolinkoMS , BremH , Tomic‐CanicM . Growth factors and cytokines in wound healing. Wound Repair and Regeneration2008;16:585‐601. ">Barrientos 2008</a>; <a href="./references#CD008548-bbs2-0062" title="BennettSP , GriffithsGD , SchorAM , LeeseGP , SchorSL . Growth factors in the treatment of diabetic foot ulcers. The British Journal of Surgery2003;90:133‐46. ">Bennet 2003</a>; <a href="./references#CD008548-bbs2-0063" title="BlairP , FlaumenhaftR . Platelet alpha‐granules: basic biology and clinical correlates. Blood Reviews2009;23(4):177‐89. ">Blair 2009</a>; <a href="./references#CD008548-bbs2-0073" title="CrucianiM , LipskyBA , MengoliC , deLallaF . Granulocyte‐colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006810] ">Cruciani 2009</a>; <a href="./references#CD008548-bbs2-0077" title="FosterTE , PuskasBL , MandelbaumBR , GerhardtMB , RodeoSA . Platelet‐rich plasma: from basic science to clinical applications. The American Journal of Sports Medicine2009;37(11):2259‐72. ">Foster 2009</a>; <a href="./references#CD008548-bbs2-0079" title="GalkowskaH , WojewodzkaU , OlszewskiWL . Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair and Regeneration2006;14:558‐65. ">Galkoswka 2006</a>; <a href="./references#CD008548-bbs2-0082" title="Grazul‐BilskaAT , JohnsonML , BilskiJJ , RedmerDA , ReynoldsLP , AbdullahA , et al. Wound healing: the role of growth factors. Drugs of Today2003;39:787‐800. ">Grazul‐Bilska 2003</a>; <a href="./references#CD008548-bbs2-0147" title="RozmanP , BoltaZ . Use of platelet growth factors in treating wounds and soft‐tissue injuries. Acta Dermatovenerologica Alpina, Panonica, et Adriatica2007;16(4):156‐65. ">Rozman 2007</a>; <a href="./references#CD008548-bbs2-0159" title="SmythSS , McEverRP , WeyrichAS , MorrellCN , HoffmanMR , ArepallyGM , et al. Platelet functions beyond hemostasis. Journal of Thrombosis and Haemotasis2009;7(11):1759‐66. ">Smyth 2009</a>). Growth factors are administered topically (on the surface) (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>), or intra lesionally (within the wound) (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>). </p> </section> <section id="CD008548-sec-0028"> <h3 class="title" id="CD008548-sec-0028">How the intervention might work</h3> <p>Normal wound healing has four phases: coagulation, inflammation, migration/proliferation, and remodelling (<a href="./references#CD008548-bbs2-0134" title="PapanasN , MaltezosE . Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clinical Interventions in Aging2008;3:233‐40. ">Papanas 2008</a>). <a href="./references#CD008548-bbs2-0153" title="SheehanP , JonesP , GiuriniJM , CaselliA , VevesA . Percent change in wound area of diabetic foot ulcers over a 4‐week period is a robust predictor of complete healing in a 12‐week prospective trial. Plastic and Reconstructive Surgery2006;117(7 Suppl):239‐44. ">Sheehan 2006</a> observed that a 53% or greater reduction in the area of a foot ulcer area after four weeks of observation was a robust predictor of healing at 12 weeks. Since chronic wound healing may be limited by a lack of the necessary growth factors, healing may be speeded up by replacing or stimulating these growth factors, so enhancing the formation of granulation tissue, that precedes healing, within the wounds (<a href="./references#CD008548-bbs2-0051" title="AmeryCM . Growth factors and the management of the diabetic foot. Diabetic Medicine2005;22 Suppl 1:12‐4. ">Amery 2005</a>; <a href="./references#CD008548-bbs2-0058" title="BarrientosS , StojadinovicO , GolinkoMS , BremH , Tomic‐CanicM . Growth factors and cytokines in wound healing. Wound Repair and Regeneration2008;16:585‐601. ">Barrientos 2008</a>; <a href="./references#CD008548-bbs2-0062" title="BennettSP , GriffithsGD , SchorAM , LeeseGP , SchorSL . Growth factors in the treatment of diabetic foot ulcers. The British Journal of Surgery2003;90:133‐46. ">Bennet 2003</a>; <a href="./references#CD008548-bbs2-0079" title="GalkowskaH , WojewodzkaU , OlszewskiWL . Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair and Regeneration2006;14:558‐65. ">Galkoswka 2006</a>; <a href="./references#CD008548-bbs2-0082" title="Grazul‐BilskaAT , JohnsonML , BilskiJJ , RedmerDA , ReynoldsLP , AbdullahA , et al. Wound healing: the role of growth factors. Drugs of Today2003;39:787‐800. ">Grazul‐Bilska 2003</a>; <a href="./references#CD008548-bbs2-0113" title="KövekerGB . Growth factors in clinical practice. International Journal of Clinical Practice2000;54:590‐3. ">Köveker 2000</a>; <a href="./references#CD008548-bbs2-0138" title="PradhanL , NabzdykC , AndersenND , LoGerfoFW , VevesA . Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Reviews in Molecular Medicine2009;11:e2. ">Pradhan 2009</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>). See <a href="./appendices#CD008548-sec-0106">Appendix 4</a> for wound‐healing and tissue‐forming ability of growth factors. </p> </section> <section id="CD008548-sec-0029"> <h3 class="title" id="CD008548-sec-0029">Why it is important to do this review</h3> <p>Diabetic foot ulcers represent a pervasive and important problem for people suffering from diabetes mellitus. Foot‐related problems are responsible for up to 50% of diabetes‐related hospital admissions (<a href="./references#CD008548-bbs2-0049" title="AlbertS . Cost‐effective management of recalcitrant diabetic foot ulcers. Clinics in Podiatric Medicine and Surgery2002;19:483‐91. ">Albert 2002</a>; Boulton 2001; <a href="./references#CD008548-bbs2-0064" title="BoultonAJ , VileikyteL , Ragnarson‐TennvallG , ApelqvistJ . The global burden of diabetic foot disease. Lancet2005;366:1719‐24. ">Boulton 2005</a>). Foot ulcers cause a low quality of life and often lead to lower extremity amputation (<a href="./references#CD008548-bbs2-0053" title="ArmstrongDG , LaveryLA , WrobelJS , VileikyteL . Quality of life in healing diabetic wounds: does the end justify the means?. Journal of Foot and Ankle Surgery2008;47:278‐82. ">Armstrong 2008</a>; <a href="./references#CD008548-bbs2-0066" title="BoutoilleD , FérailleA , MaulazD , KrempfM . Quality of life with diabetes‐associated foot complications: comparison between lower‐limb amputation and chronic foot ulceration. Foot and Ankle International2008;29:1074‐8. ">Boutoille 2008</a>; <a href="./references#CD008548-bbs2-0081" title="GoodridgeD , TrepmanE , SloanJ , GuseL , StrainLA , McIntyreJ , et al. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot and Ankle International2006;27:274‐80. ">Goodridge 2006</a>; <a href="./references#CD008548-bbs2-0094" title="HerberOR , SchneppW , RiegerMA . A systematic review on the impact of leg ulceration on patients' quality of life. Health and Quality of Life Outcomes2007;25:44. ">Herber 2007</a>; <a href="./references#CD008548-bbs2-0111" title="KinmondK , McGeeP , GoughS , AshfordR . 'Loss of self': a psychosocial study of the quality of life of adults with diabetic foot ulceration. Journal of Tisssue Viability2003;13:6‐8, 10, 12. ">Kinmond 2003</a>; <a href="./references#CD008548-bbs2-0125" title="MeatherallBL , GarrettMR , KaufertJ , MartinBD , FrickeMW , ArnejaAS , et al. Disability and quality of life in Canadian aboriginal and non‐aboriginal diabetic lower‐extremity amputees. Archives of Physical Medicine and Rehabilitation2005;86:1594‐602. ">Meatherall 2005</a>; <a href="./references#CD008548-bbs2-0139" title="PriceP . The diabetic foot: quality of life. Clinical Infectious Diseases2004;39(Suppl 2):129‐31. ">Price 2004</a>; <a href="./references#CD008548-bbs2-0144" title="RibuL , BirkelandK , HanestadBR , MoumT , RustoenT . A longitudinal study of patients with diabetes and foot ulcers and their health‐related quality of life: wound healing and quality‐of‐life changes. Journal of Diabetes Complications2008;22:400‐7. ">Ribu 2008</a>; <a href="./references#CD008548-bbs2-0149" title="SchaperNC , ApelqvistJ , BakkerK . Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia2012;55(7):1869‐72. ">Schaper 2012a</a>; <a href="./references#CD008548-bbs2-0162" title="ValensiP , GirodI , BaronF , Moreau‐DefargesT , GuillonP . Quality of life and clinical correlates in patients with diabetic foot ulcers. Diabetes and Metabolism2005;31(3 Pt 1):263‐71. ">Valensi 2007</a>). Amputation causes prolonged hospitalisation, rehabilitation, and an increased need for home care and social services (<a href="./references#CD008548-bbs2-0050" title="AliS , FareedA , HumailS , BasitA , AhmedaniM , FawwadA , et al. The personal cost of diabetic foot disease in the developing world ‐ a study from Pakistan. Diabetic Medicine2008; Vol. 25:1231‐3. ">Ali 2008</a>; <a href="./references#CD008548-bbs2-0054" title="AshryHR , LaveryLA , ArmstrongDG , LaveryDC , vanHoutumWH . Cost of diabetes‐related amputations in minorities. The Journal of Foot and Ankle Surgery1998;37:186‐90. ">Ashry 1998</a>; <a href="./references#CD008548-bbs2-0080" title="GirodI , ValensiP , LaforêtC , Moreau‐DefargesT , GuillonP , BaronF . An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients. Diabetes and Metabolism2003;29:269‐77. ">Girod 2003</a>; <a href="./references#CD008548-bbs2-0093" title="HabibSH , BiswasKB , AkterS , SahaS , AliL . Cost‐effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh. Journal of Diabetes and its Complications2010;24(4):259‐64. ">Habib 2010</a>; <a href="./references#CD008548-bbs2-0115" title="LantisJC2nd , BooneD , GendicsC , ToddG . Analysis of patient cost for recombinant human platelet‐derived growth factor therapy as the first‐line treatment of the insured patient with a diabetic foot ulcer. Advances in Skin and Wound Care2009;22:167‐71. ">Lantis 2009</a>; <a href="./references#CD008548-bbs2-0143" title="RedekopWK , StolkEA , KokE , LovasK , KaloZ , BusschbachJJ . Diabetic foot ulcers and amputations: estimates of health utility for use in cost‐effectiveness analyses of new treatments. Diabetes and Metabolism2004;30:549‐56. ">Redekop 2004</a>; <a href="./references#CD008548-bbs2-0156" title="SiriwardanaHD , WeerasekeraD . The cost of diabetic foot conditions. The Ceylon Medical Journal2007;52:89‐91. ">Siriwardana 2007</a>; <a href="./references#CD008548-bbs2-0163" title="VanAckerK , Oleen‐BurkeyM , DeDeckerL , VanmaeleR , VanSchilP , MatricaliG , et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Research and Clinical Practice2000;50:87‐95. ">Van Acker 2000</a>; <a href="./references#CD008548-bbs2-0166" title="ViswanathanV , ThomasN , TandonN , AsirvathamA , RajasekarS , RamachandranA , et al. Profile of diabetic foot complications and its associated complications ‐ a multicentric study from India. The Journal of Association Physicians of India2005;53:933‐6. ">Viswanathan 2005</a>; <a href="./references#CD008548-bbs2-0171" title="WillrichA , PinzurM , McNeilM , JuknelisD , LaveryL . Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study. Foot and Ankle International2005;26:128‐34. ">Willrich 2005</a>). Management of the diabetic foot has major economic consequences for patients, their families and society (<a href="./references#CD008548-bbs2-0107" title="JeffcoateWJ , HardingKG . Diabetic Foot Ulcers. Lancet2003;361:1545‐51. ">Jeffcoate 2003</a>; <a href="./references#CD008548-bbs2-0108" title="JeffcoateWJ , vanHoutumWH . Amputation as a marker of the quality of foot care in diabetes. Diabetologia2004;47:2051‐8. ">Jeffcoate 2004</a>; <a href="./references#CD008548-bbs2-0126" title="MilmanMHSA , LemeCBM , BorelliDT , KaterFR , BacciliECDC , RochaRCM , et al. Diabetic foot: evaluation of evolution and hospital cost of hospitalized patients in Conjunto Hospitalar de Sorocaba. Arquivos Brasileiros de Endocrinologia e Metabologia2001;45:447‐51. ">Milman 2001</a>; <a href="./references#CD008548-bbs2-0142" title="RathurHM , BoultonAJ . The diabetic foot. Clinics in Dermatology2007;25:109‐20. ">Rathur 2007</a>; <a href="./references#CD008548-bbs2-0158" title="SmithD , CullenMJ , NolanJJ . The cost of managing diabetic foot ulceration in an Irish hospital. Irish Journal of Medical Science2004;173:89‐92. ">Smith 2004</a>), and quality of life for caregivers is also unsatisfactory (<a href="./references#CD008548-bbs2-0129" title="Nabuurs‐FranssenMH , HuijbertsMS , Nieuwenhuijzen KrusemanAC , WillemsJ , SchaperNC . Health‐related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia2005;48:1906‐10. ">Nabuurs‐Frassen 2005</a>). </p> <p>Several randomised clinical trials (RCTs) have assessed the benefits and harms of growth factors for treating diabetic foot ulcers, and they need a critical appraisal for risk of systematic errors that can cause bias (that is, could cause overestimation of benefits and underestimation of harms) and risk of random errors (that is, play of chance). Several narrative reviews and meta‐analyses have assessed the use of growth factors for treating diabetic foot ulcers, but these have been prone to errors (that is, lack of rigorous assessment of bias risks; no or insufficient evaluation of the risks of random errors; no evaluation of statistical heterogeneity; poor reporting of search methods; and potential conflicts of interest as authors of the reviews were also trialists of the included trials) (<a href="./references#CD008548-bbs2-0097" title="HinchliffeRJ , ValkGD , ApelqvistJ , ArmstrongDG , BakkerK , GameFL , et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes/Metabolism Research and Reviews2008;24(Suppl 1):119–44. ">Hinchliffe 2008</a>; <a href="./references#CD008548-bbs2-0134" title="PapanasN , MaltezosE . Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clinical Interventions in Aging2008;3:233‐40. ">Papanas 2008</a>). </p> <p>A systematic review of the most up to date evidence, including a rigorous assessment of the quality of that evidence, may help clinicians and clinical researchers make informed decisions about the use of growth factors for treating diabetic foot ulcers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008548-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-sec-0138">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008548-sec-0030"></div> <p>To assess the benefits and harms of growth factors for diabetic foot ulcers in patients with type 1 or type 2 diabetes mellitus. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008548-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-sec-0139">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008548-sec-0031"></div> <section id="CD008548-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008548-sec-0033"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) in any setting.</p> </section> <section id="CD008548-sec-0034"> <h4 class="title">Types of participants</h4> <p>Adults (&gt;18 years of age) with a diabetic foot ulcer of any aetiology.</p> </section> <section id="CD008548-sec-0035"> <h4 class="title">Types of interventions</h4> <p>See <a href="./appendices#CD008548-sec-0103">Appendix 1</a>. </p> <section id="CD008548-sec-0036"> <h5 class="title">Experimental interventions</h5> <p> <ol id="CD008548-list-0001"> <li> <p>Platelet‐derived wound healing formula</p> </li> <li> <p>Autologous growth factor</p> </li> <li> <p>Allogeneic platelet‐derived growth factor</p> </li> <li> <p>Transforming growth factor β2</p> </li> <li> <p>Arginine‐glycine‐aspartic acid (RGD) peptide matrix</p> </li> <li> <p>Recombinant human platelet‐derived growth factor (becaplermin)</p> </li> <li> <p>Recombinant human epidermal growth factor</p> </li> <li> <p>Recombinant human basic fibroblast growth factor</p> </li> <li> <p>Recombinant human vascular endothelial growth factor (telbermin)</p> </li> <li> <p>Recombinant human lactoferrin</p> </li> <li> <p>Recombinant human acidic fibroblast growth factor</p> </li> </ol> </p> <p>In addition to receiving the experimental intervention (growth factors) participants also received standard care (see below). </p> <p>Trials of granulocyte‐colony stimulating factors were excluded as they are the focus of another Cochrane review (<a href="./references#CD008548-bbs2-0073" title="CrucianiM , LipskyBA , MengoliC , deLallaF . Granulocyte‐colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006810] ">Cruciani 2009</a>). </p> </section> <section id="CD008548-sec-0037"> <h5 class="title">Control interventions</h5> <p> <ol id="CD008548-list-0002"> <li> <p>Standard care (for example, antibiotic therapy, debridement, wound dressings) alone or plus placebo. </p> </li> </ol> </p> <p>We noted whether the standard care was delivered similarly to intervention groups and noted any differences between intervention groups. </p> </section> </section> <section id="CD008548-sec-0038"> <h4 class="title">Types of outcome measures</h4> <section id="CD008548-sec-0039"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008548-list-0003"> <li> <p>Complete wound healing (defined as 100% epithelialisation or skin closure without drainage). </p> </li> <li> <p>Lower limb amputation (minimum of one toe).</p> </li> <li> <p>Time to complete healing of the diabetic foot ulcer.</p> </li> </ol> </p> </section> <section id="CD008548-sec-0040"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008548-list-0004"> <li> <p>Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence).</p> </li> <li> <p>Quality of life (as measured by a validated scale).</p> </li> <li> <p>Adverse events: number and type of adverse events defined as any untoward medical occurrence ‐ not necessarily having a causal relationship with the treatment. We reported separately on adverse events that led, and did not lead, to treatment discontinuation. We defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines as any event that at any dose results in death, is life‐threatening, requires in‐patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability, or is a congenital anomaly/birth defect, and any important medical event that may have jeopardised the patient or requires intervention to prevent it (<a href="./references#CD008548-bbs2-0100" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). All other adverse events were considered non‐serious. </p> </li> </ol> </p> </section> </section> </section> <section id="CD008548-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008548-sec-0042"> <h4 class="title">Electronic searches</h4> <p>The following electronic databases were searched to identify reports of relevant randomised clinical trials: </p> <p> <ol id="CD008548-list-0005"> <li> <p>The Cochrane Wounds Group Specialised Register (searched 03 March 2015);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2015, Issue 2); </p> </li> <li> <p>Ovid MEDLINE (1946 to March 2, 2015);</p> </li> <li> <p>Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations) (March 2, 2015);</p> </li> <li> <p>Ovid EMBASE (1974 to March 2, 2015);</p> </li> <li> <p>EBSCO CINAHL (1982 to March 3, 2015).</p> </li> </ol> </p> <p>We used the following search strategy in The Cochrane Central Register of Controlled Trials (CENTRAL): </p> <p> <ol id="CD008548-list-0006"> <li> <p>MeSH descriptor Foot Ulcer explode all trees</p> </li> <li> <p>MeSH descriptor Diabetic Foot explode all trees</p> </li> <li> <p>diabet* NEAR/3 ulcer*:ti,ab,kw</p> </li> <li> <p>diabet* NEAR/3 (foot or feet):ti,ab,kw</p> </li> <li> <p>diabet* NEAR/3 wound*:ti,ab,kw</p> </li> <li> <p>(#1 OR #2 OR #3 OR #4 OR #5)</p> </li> <li> <p>MeSH descriptor Intercellular Signaling Peptides and Proteins explode all trees</p> </li> <li> <p>MeSH descriptor Insulin‐Like Growth Factor Binding Proteins explode all trees</p> </li> <li> <p>growth NEXT factor*:ti,ab,kw</p> </li> <li> <p>EGF or FGF or PDGF:ti,ab,kw</p> </li> <li> <p>plermin or regranex or becaplermin:ti,ab,kw</p> </li> <li> <p>(#7 OR #8 OR #9 OR #10 OR #11)</p> </li> <li> <p>(#6 AND #12)</p> </li> </ol> </p> <p>This strategy was adapted to search Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL (please see <a href="./appendices#CD008548-sec-0107">Appendix 5</a>). The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximizing version (2008 revision) (<a href="./references#CD008548-bbs2-0120" title="LefebvreC , ManheimerE , GlanvilleJ , on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefevbre 2011</a>). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="./references#CD008548-bbs2-0155" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 12 March 2010). ">SIGN 2010</a>). There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD008548-sec-0043"> <h4 class="title">Searching other resources</h4> <p>The following web sites were also searched:</p> <p> <ol id="CD008548-list-0007"> <li> <p>Food and Drug Administration (<a href="http://www.fda.gov/" target="_blank">http://www.fda.gov/</a>); </p> </li> <li> <p>European Medicines Agency (<a href="http://www.emea.europa.eu" target="_blank">http://www.emea.europa.eu</a>); </p> </li> <li> <p>International Working Group on the Diabetic Foot (<a href="http://iwgdf.org/" target="_blank">http://iwgdf.org/</a>); </p> </li> <li> <p>MedWatch The FDA Safety Information and Adverse Event Reporting Program (<a href="http://www.fda.gov/Safety/MedWatch/default.htm" target="_blank">http://www.fda.gov/Safety/MedWatch/default.htm</a>); </p> </li> <li> <p>Medicines and Healthcare products Regulatory Agency (<a href="http://www.mhra.gov.uk/index.htm" target="_blank">http://www.mhra.gov.uk/index.htm</a>); </p> </li> <li> <p>Scirus (<a href="http://www.scirus.com" target="_blank">www.scirus.com</a>); </p> </li> <li> <p>CenterWatch (<a href="http://www.centerwatch.com" target="_blank">http://www.centerwatch.com</a>); </p> </li> <li> <p>Evidence in Health and Social Care (<a href="http://www.evidence.nhs.uk/" target="_blank">http://www.evidence.nhs.uk/</a>); </p> </li> <li> <p>Dailymed (<a href="http://dailymed.nlm.nih.gov/dailymed/about.cfm" target="_blank">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a>). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). </p> </li> </ol> </p> <p>We also checked the reference lists of all the potentially relevant trials identified by the above methods. </p> </section> </section> <section id="CD008548-sec-0044"> <h3 class="title" id="CD008548-sec-0044">Data collection and analysis</h3> <p>We summarised data using standard Cochrane Collaboration methodologies (<a href="./references#CD008548-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <section id="CD008548-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AJM‐C, SN) independently assessed each reference identified by the search against the inclusion criteria. We resolved disagreements that arose through discussion. Those references that appeared to meet the inclusion criteria were retrieved in full for further independent assessment by two review authors. </p> </section> <section id="CD008548-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>One review author independently extracted data (SN) from the included trials using a spreadsheet data extraction form and two review authors (AJM‐C, DSR) checked the data entered. We extracted the following data: eligibility criteria, demographics (age, sex, country), characteristic of the ulcers (anatomic site, size, number of ulcers, presence of infection, duration of ulceration), type of diabetes mellitus, duration of diabetes mellitus, ulcer treatments, and outcomes assessed. We discussed any discrepancies between review authors in order to achieve a final consensus. </p> </section> <section id="CD008548-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Independently, three review authors (AJM‐C, SN, DSR) assessed the risk of bias of each included trial using the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> 5.1.0 (<a href="./references#CD008548-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). See, <a href="./appendices#CD008548-sec-0108">Appendix 6</a> for details. </p> <p>Three review authors (LR, PO, JCT) checked these assessments. The review authors discussed discrepancies and achieved consensus. </p> <section id="CD008548-sec-0048"> <h5 class="title">Overall risk of bias</h5> <p>We made explicit judgements about whether the RCTs were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008548-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the risk of bias as being high if any of the above domains was assessed as being at unclear or high risk of bias. </p> <p>Trials that had adequate generation of allocation sequence, allocation concealment, blinding, handling of incomplete outcome data, and no selective outcome reporting, and that were without other risks of bias were considered to be trials with a low risk of bias. We explored the impact of the risk of bias through undertaking subgroup analyses. </p> </section> </section> <section id="CD008548-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, such as incidence of complete wound healing, amputation, and adverse events, we calculated the risk ratio (RR) with 95% confidence intervals (CI) for each. For ulcer‐free days following treatment, a time‐to‐event outcome, we calculated the hazard ratio (HR) with 95% CI (<a href="./references#CD008548-bbs2-0175" title="ZavalaD , Martí‐CarvajalA , Peña‐MartiG , Comunián‐CarrascoG . Software for data transformation for time‐to‐event outcomes (alfa version). Valencia: Universidad de Carabobo, 2007. ">Zavala 2007</a>). </p> </section> <section id="CD008548-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>We assessed the percentage of dropouts for each included trial, and for each intervention group, and evaluated whether an intention‐to‐treat (ITT) analysis had been performed or could have been performed from the available published information. We contacted authors to resolve some queries on this issue. </p> <p>In order to undertake an ITT analysis, we sought data from the trial authors on the number of participants in treatment groups, irrespective of compliance and whether or not participants were later thought to be ineligible, or otherwise excluded from treatment or lost to follow‐up. If this information was not forthcoming, we undertook a complete patient analysis, knowing that it might be biased. </p> <p>We included patients with incomplete or missing data in sensitivity analyses by imputing them according to the following scenarios (<a href="./references#CD008548-bbs2-0098" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7211):670‐4. ">Hollis 1999</a>). </p> <p> <ul id="CD008548-list-0008"> <li> <p>Extreme case analysis favouring the experimental intervention ('best‐worse' case scenario): none of the drop‐outs/participants lost from the experimental arm, but all of the drop‐outs/participants lost from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </li> <li> <p>Extreme case analysis favouring the control ('worst‐best' case scenario): all drop‐outs/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </li> </ul> </p> </section> <section id="CD008548-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified statistical heterogeneity using the I<sup>2</sup> statistic, which describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error (<a href="./references#CD008548-bbs2-0095" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). We considered statistical heterogeneity to be present if I<sup>2</sup> was greater than 50% (<a href="./references#CD008548-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When significant heterogeneity was detected (i.e. when I<sup>2</sup> exceeded 50%), we attempted to identify the possible causes of heterogeneity. </p> </section> <section id="CD008548-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias and other bias by a funnel‐plot (<a href="./references#CD008548-bbs2-0160" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). We calculated Egger's test with Comprehensive Meta‐analysis software (<a href="./references#CD008548-bbs2-0072" title="Comprehensive Meta‐Analysis team. Comprehensive Meta‐Analysis Sofware. Version 2.2.064. Englewood, NJ: Biostat, Inc, 2011. ">CMA 2011</a>). </p> </section> <section id="CD008548-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We calculated pooled estimates and 95% confidence intervals (CI) using fixed‐effect model. </p> </section> <section id="CD008548-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had anticipated clinical heterogeneity in the effect of the intervention and we planned to conduct the following sub‐group analyses had the data had been available. Furthermore, subgroup analysis would be performed only for complete wound healing (primary outcome). </p> <p>We could not perform preplanned analyses for clinical subgroups (insulin‐using compared to non insulin‐using participants, severity and depth of wound, and use or not of antibiotics (<a href="./appendices#CD008548-sec-0115">Appendix 7</a>; <a href="./appendices#CD008548-sec-0116">Appendix 8</a>)) due to a lack of available data.<br/> <br/> We conducted the following preplanned subgroup analyses. </p> <p> <ol id="CD008548-list-0009"> <li> <p>Duration of follow‐up: trials with less 20 weeks of follow‐up compared to trials with 20 weeks or more of follow‐up. </p> </li> <li> <p>Type of growth factor.</p> </li> </ol> </p> <p>The subgroup analyses were only performed for the outcome of complete wound closure.</p> </section> <section id="CD008548-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analysis in order to explore the influence of these factors on the intervention effect size. </p> <p> <ol id="CD008548-list-0010"> <li> <p>Repeating the analysis taking attrition bias into consideration: 'Best‐worst case' scenario versus 'Worst‐best case' scenario </p> </li> </ol> </p> <section id="CD008548-sec-0056"> <h5 class="title">'Summary of findings' tables</h5> <p>We used the principles of the GRADE system to assess the quality of the body of evidence associated with specific outcomes where possible (complete wound closure, lower limb amputation, ulcer‐free day following treatment for diabetic foot ulcers, time to complete healing of the diabetic foot ulcer, quality of life, and adverse events) (<a href="./references#CD008548-bbs2-0088" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011f</a>). We constructed 'Summary of findings' tables using the GRADE software. The GRADE approach appraises the quality of a body of evidence on the basis of the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within‐study risk of bias (methodologic quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD008548-bbs2-0057" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>; <a href="./references#CD008548-bbs2-0083" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. ">Guyatt 2011a</a>; <a href="./references#CD008548-bbs2-0084" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011b</a>; <a href="./references#CD008548-bbs2-0085" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. ">Guyatt 2011c</a>; <a href="./references#CD008548-bbs2-0086" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. ">Guyatt 2011d</a>; <a href="./references#CD008548-bbs2-0087" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. ">Guyatt 2011e</a>; <a href="./references#CD008548-bbs2-0088" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011f</a>; <a href="./references#CD008548-bbs2-0089" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. ">Guyatt 2011g</a>; <a href="./references#CD008548-bbs2-0090" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. ">Guyatt 2011h</a>; <a href="./references#CD008548-bbs2-0091" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. ">Guyatt 2011i</a>; <a href="./references#CD008548-bbs2-0092" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. ">Guyatt 2012</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008548-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008548-sec-0057"></div> <section id="CD008548-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD008548-sec-0059"> <h4 class="title">Results of the search</h4> <p>We identified 424 references using our search strategies. Twenty‐eight trials (35 references) involving 2365 participants met our inclusion criteria (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). See <a href="#CD008548-fig-0001">Figure 1</a> for details of the flow of studies. </p> <div class="figure" id="CD008548-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008548-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008548-sec-0060"> <h4 class="title">Included studies</h4> <p>Tables of <a href="./references#CD008548-sec-0127" title="">Characteristics of included studies</a> show a detailed description of the studies. </p> <section id="CD008548-sec-0061"> <h5 class="title">Growth factors and populations assessed in the trials</h5> <p>The 28 RCTs reported 11 different growth factors compared with several different control interventions. </p> <p>The experimental interventions included both non‐recombinant and recombinant growth factors. The non‐recombinant growth factors investigated were: platelet‐derived wound healing formula (<a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>); autologous growth factors (<a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>); allogeneic platelet‐derived growth factor (<a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>); transforming growth factor β2 (<a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>); arginine‐glycine‐aspartic acid (RGD) peptide matrix (<a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>). The recombinant growth factors were recombinant human platelet‐derived growth factor (<a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>); recombinant human epidermal growth factors (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>); recombinant human basic fibroblast growth factors (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>); recombinant human vascular endothelial growth factor (<a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>); recombinant human lactoferrin (<a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>); and recombinant human acidic fibroblast growth factor (<a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>). </p> <p>Twenty trials compared growth factors against no growth factor or against placebo (without or with co‐interventions). The comparisons were: no growth factor (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>); saline solution (<a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>); or placebo (<a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). The characteristics of the placebo were not sufficiently described in <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>, <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>, <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>, <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>, or <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>. Accordingly, only four trials used an appropriate placebo (<a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>). </p> <p>Two trials compared one growth factor versus another growth factor, or different doses of the same growth factor (with or without co‐interventions). <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a> compared recombinant human acidic fibroblast growth factor versus recombinant human basic fibroblast growth factor. <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a> compared two doses of recombinant human epidermal growth factor, 75 µg and 25 µg. </p> <p>Six trials compared growth factors versus other interventions (with or without co‐interventions): silver sulphadiazine (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>); insulin (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>); oxidized regenerated cellulose/collagen biomaterial (<a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>); moisture‐regulating dressing (<a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>); oasis wound matrix (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>); and actovegin (<a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>). </p> <p>The co‐interventions used most frequently in both the experimental and the control groups were: wound debridement (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007;</a><a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992;</a><a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>); wound dressing (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>, <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007;</a><a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002;</a><a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992;</a><a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>); antibiotics ‐ topical (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>), and systemic (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007;</a><a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>); glycaemic control (<a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005;</a><a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995;</a><a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>); and offloading of local pressure on the foot ulcer (<a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995;</a><a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002;</a><a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992;</a><a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>). Two trials did not report the use of any co‐intervention (<a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>). </p> <p>Twenty‐six trials administered the intervention topically; two trials involving recombinant human epidermal growth factor used intralesional administration (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>). </p> <p>The intervention was administered: once daily in 12 trials (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>); daily during the six weeks for which participants were inpatients, then twice a week for 12 weeks in one trial (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>); twice daily in three trials (<a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>); once a week in one trial (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>); twice a week in two trials (<a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>); or three times a week on alternate days in three trials (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>). Six trials did not report on the frequency of administration (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>). </p> <p>The mean age of participants was 59.1 years (standard deviation (SD) ± 4.16), and most were male (66.6% (SD ± 16.1%)). Ten trials included participants with type 1 and type 2 diabetes mellitus (<a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). Eighteen trials did not report the type of diabetes mellitus explicitly (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). Trials included participants with target foot ulcers at nine different sites (fore‐foot, mid‐foot, hind‐foot, internal and external edge, sole, plantar surface, ankle). Six trials included participants with neuropathic ulcers (<a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>). The remaining 22 trials did not report the cause of the foot ulcers. Generally, the trials were conducted in the out‐patient (ambulatory) setting. </p> </section> <section id="CD008548-sec-0062"> <h5 class="title">Location of trials</h5> <p>The trials were conducted in ten countries: three in China (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>); two in Cuba (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>); one in Greece (<a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>); five in India (<a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>); one in Iran (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>); one in Italy (<a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>); one in Japan (<a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>); and eleven in the USA (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). One trial was conducted in both Canada and the USA (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>), and another in both France and Italy (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>). </p> </section> <section id="CD008548-sec-0063"> <h5 class="title">Trial methods</h5> <p>All trials were conducted using the parallel group trial design. Eighty‐two per cent of the trials (23/28) were conducted without reporting an <i>a priori</i> estimation of sample size. Trials were small with sample sizes ranging from 13 to 382 participants, with a median sample size of 60 and a mean of 87 (± SD 76). Fourteen trials had follow‐up periods of less than 20 weeks (range five to 18 weeks) (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>). Thirteen trials had a follow‐up of 20 weeks or more (range 20 weeks to 26 weeks) (<a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). One trial did not report length of follow‐up (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>). In the trials, the units of randomisation and analysis were the participants. In terms of assessing the stage of the ulcer ‐ trials variously used Wagner's classification, the University of Texas Diabetic classification, or the International Association Enterostomal Therapy classification for (<a href="./appendices#CD008548-sec-0105">Appendix 3</a>). <a href="./appendices#CD008548-sec-0117">Appendix 9</a> shows the methods for assessing ulcer dimension. </p> </section> </section> <section id="CD008548-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded nine studies for the following reasons: case reports (<a href="./references#CD008548-bbs2-0029" title="AcostaJB , SavigneW , ValdezC , FrancoN , AlbaJS , delRioA , et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. International Wound Journal2006;3(3):232‐9. ">Acosta 2006</a>; <a href="./references#CD008548-bbs2-0033" title="MillerMS . Use of topical recombinant human platelet‐derived growth factor‐BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers. The Journal of Foot and Ankle Surgery1999;38:227‐31. ">Miller 1999</a>; <a href="./references#CD008548-bbs2-0036" title="TuyetHL , QuynhTTN , MinhHVH , BichDNT , DinhTD , TanDL , et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. International Wound Journal2009;6:159‐66. ">Tuyet 2009</a>); non‐RCTs (<a href="./references#CD008548-bbs2-0030" title="AminianB , ShamsM , SoveydM , OmraniGhR . Topical autologous platelet‐derived growth factors in the treatment of chronic diabetes ulcers. Archives of Iranian Medicine2000; Vol. 3, issue 2:55‐9. ">Aminian 2000</a>; <a href="./references#CD008548-bbs2-0035" title="Saad SettaH , ElshahatA , ElsherbinyK , MassoudK , SafeI . Platelet‐rich plasma versus platelet‐poor plasma in the management of chronic diabetic foot ulcers: a comparative study. International Wound Journal2011;8(3):307‐12. ">Saad Setta 2011</a>); case series (<a href="./references#CD008548-bbs2-0031" title="EmbilJM , PappK , SibbaldG , TousignantJ , SmiellJM , WongB , The Canadian Becaplermin Study Group. Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy. Wound Repair and Regeneration2000;8:162‐8. ">Embil 2000</a>; <a href="./references#CD008548-bbs2-0032" title="HongJP , JungHD , KimYW . Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Annals of Plastic Surgery2006;56:394‐8. ">Hong 2006</a>); and phase IV study (post‐marketing surveillance study) (<a href="./references#CD008548-bbs2-0034" title="MohanVK . Recombinant human epidermal growth factor (REGEN‐D 150): effect on healing of diabetic foot ulcers. Diabetes Research and Clinical Practice2007;78:405‐11. ">Mohan 2007</a>; <a href="./references#CD008548-bbs2-0037" title="Yera‐AlosIB , Alonso‐CarbonellL , Valenzuela‐SilvaCM , Tuero‐IglesiasAD , Moreira‐MartinezM , Marrero‐RodriguezI , et al. Active post‐marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacology and Toxicology2013;14:44. ">Yera‐Alos 2013</a>). See the <a href="./references#CD008548-sec-0128" title="">Characteristics of excluded studies</a> table. </p> <section id="CD008548-sec-0065"> <h5 class="title">Ongoing trials</h5> <p>We identified six ongoing trials (<a href="./references#CD008548-bbs2-0042" title="NCT00521937 . Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer. https://clinicaltrials.gov/ct2/show/NCT00521937. ">NCT00521937</a>; <a href="./references#CD008548-bbs2-0043" title="NCT00709514 . Clinical Evaluation of DCB‐WH1 in Healing of Chronic Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT00709514. ">NCT00709514</a>; <a href="./references#CD008548-bbs2-0044" title="NCT00915486 . A Dose Finding Study of Topically Applied I‐020201 as an Adjunct to Good Standard‐of‐care in Patients With Chronic Diabetic Foot Ulcers (DFU). https://clinicaltrials.gov/ct2/show/NCT00915486. ">NCT00915486</a>; <a href="./references#CD008548-bbs2-0045" title="NCT00926068 . Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal). https://clinicaltrials.gov/ct2/show/NCT00926068. ">NCT00926068</a>; <a href="./references#CD008548-bbs2-0046" title="NCT01060670 . A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT01060670. ">NCT01060670</a>; <a href="./references#CD008548-bbs2-0047" title="NCT01098357 . Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer. https://clinicaltrials.gov/ct2/show/NCT01098357. ">NCT01098357</a>). Full details are shown in the table of <a href="./references#CD008548-sec-0130" title="">Characteristics of ongoing studies</a>. </p> </section> <section id="CD008548-sec-0066"> <h5 class="title">Studies awaiting classification</h5> <p>Four citations are 'Awaiting classification' (<a href="./references#CD008548-bbs2-0038" title="Gomez‐VillaR , Aguilar‐RebolledoF , Lozano‐PlatonoffA , Teran‐SotoJM , Fabian‐VictorianoMR , Kresch‐TronikNS , et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double‐blinded controlled trial. Wound Repair and Regeneration2014;22(4):497‐503. ">Gomez‐Villa 2014</a>; <a href="./references#CD008548-bbs2-0039" title="MorimotoN , YoshimuraK , NiimiM , ItoT , AyaR , FujitakaJ , et al. Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers. Tissue engineering2013 Part A;19(17‐18):1931‐40. ">Morimoto 2013</a>; <a href="./references#CD008548-bbs2-0040" title="SinglaS , GargR , KumarA , GillC . Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: Comparative analysis of 50 patients. Journal of Natural Science, Biology and Medicine2014;5(2):273‐7. ">Singla 2014</a>; <a href="./references#CD008548-bbs2-0041" title="YoungMJ , LarsenJ , KnowlesA , ParnellL , WardJD . The treatment of diabetic neuropathic foot ulcers with biosynthetic platelet derived growth factor. Diabetic Medicine1992, (Suppl 2):S42. ">Young 1992</a>; see <a href="./references#CD008548-sec-0129" title="">Characteristics of studies awaiting classification</a> for details). </p> </section> </section> </section> <section id="CD008548-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in the included trials is summarised in <a href="#CD008548-fig-0002">Figure 2</a> and <a href="#CD008548-fig-0003">Figure 3</a>, and detailed in the <a href="./references#CD008548-sec-0127" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD008548-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008548-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008548-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008548-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008548-sec-0068"> <h4 class="title">Allocation</h4> <section id="CD008548-sec-0069"> <h5 class="title">Random sequence generation</h5> <p>The risk of bias arising from the method of generation of the allocation sequence was considered to be low in eleven trials (<a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). The remaining 17 trials had unclear risk of bias for this domain. </p> </section> <section id="CD008548-sec-0070"> <h5 class="title">Allocation concealment</h5> <p>The risk of bias arising from the method of allocation concealment was considered to be low in two trials (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). The remaining 26 trials had an unclear risk for this domain. </p> </section> </section> <section id="CD008548-sec-0071"> <h4 class="title">Blinding</h4> <p>The risk of bias due to lack of blinding of participants and personnel was rated as low in 11 trials (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). The risk of bias of performance bias was high in the remaining 17 trials. </p> <p>In four trials outcome assessment was clearly reported as blinded, and detection bias was considered to be low (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). Blinding of outcome assessors was unclear or not performed in the remaining 24 trials, so the risk of detection bias was considered to be high. </p> </section> <section id="CD008548-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was rated as low in six trials (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0027" title="ViswanathanV , PendseyS , SekarN , MurthyGSR . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐D 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>), but high in the remaining 22 trials. </p> </section> <section id="CD008548-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Risk of selective outcome reporting bias was rated as low in three trials (<a href="./references#CD008548-bbs2-0002" title="AgrawalRP , JhajhariaA , MothaN , DograR , ChaudhariV , NayakKC . Use of a platelet‐derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot Journal2009;12(2):80‐8. ">Agrawal 2009</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>), two trials was rated as having unclear risk (<a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>), and rated as high in the remaining 23 trials. It was mainly due to these trials neither measured nor reported complete wound closure or safety data. </p> </section> <section id="CD008548-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>Risk of other bias was rated as high in all 28 trials due to bias in the presentation of data or design bias. <br/> <br/> Accordingly, all trials were considered to have an overall high risk of bias. </p> </section> </section> <section id="CD008548-sec-0075"> <h3 class="title" id="CD008548-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD008548-tbl-0001"><b>Summary of findings for the main comparison</b> Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</a> </p> <section id="CD008548-sec-0076"> <h4 class="title">Primary outcomes</h4> <section id="CD008548-sec-0077"> <h5 class="title">Complete wound closure (defined as 100% epithelialisation or skin closure without drainage) </h5> <section id="CD008548-sec-0078"> <h6 class="title">Any growth factor versus placebo or no growth factor</h6> <p>Meta‐analysis of 12 trials showed that growth factors, when considered as a group, increased the incidence of complete wound healing compared with placebo or no growth factor (345/657 (52.51%) versus 167/482 (34.64%); RR fixed‐effect model 1.51 95% CI 1.31 to 1.73; I<sup>2</sup> = 51%, <i>low quality evidence due to limitation in design, execution or both, and inconsistency</i>) (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). See <a href="./references#CD008548-fig-0005" title="">Analysis 1.1</a>. <a href="#CD008548-fig-0004">Figure 4</a> shows a funnel‐plot of this meta‐analysis. </p> <div class="figure" id="CD008548-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure.P‐value (two tailed) for Egger's test = 0.43" data-id="CD008548-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure. </p> <p>P‐value (two tailed) for Egger's test = 0.43</p> </div> </div> </div> <section id="CD008548-sec-0079"> <p><b>Subgroup analysis of trials with follow‐up of less than 20 weeks compared to trials with follow‐up of 20 weeks or longer</b></p> <p>Meta‐analysis of five trials with follow‐up of less than 20 weeks shows uncertainty due to imprecision (small sample size and low rate of event) in the proportion of complete wound healing comparing any growth factor versus placebo or no growth factor (102/167 (61.07%) versus 60/119 (50.42%); RR 1.24, 95% CI 1.00 to 1.55; I<sup>2</sup> = 57%; P value 0.05) (<a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>). Meta‐analysis of seven trials with a follow‐up of 20 weeks or longer showed an increase in the incidence of complete wound healing comparing any growth factor versus placebo or no growth factor (243/490 (49.59%) versus 107/363 (29.47%); RR 1.65, 95% CI 1.38 to 1.98; I<sup>2</sup> = 34%) (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). The subgroup test showed high inconsistency between the two groups (I<sup>2</sup> = 73.5%, P value 0.05). See <a href="./references#CD008548-fig-0009" title="">Analysis 2.1</a>. </p> <p><i>Subgroup analysis by type of growth factor</i> </p> <p>One trial comparing autologous growth factor versus placebo or no growth factor showed inconclusive results regarding complete wound closure due to high imprecision (2/7 (28.57%) versus 1/7 (14.28%); RR 2.0, 95% CI 0.23 to 17.34; P value 0.53) (<a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>). Meta‐analysis of two trials comparing platelet‐derived wound healing formula versus placebo showed a significant increase in the likelihood of participants with complete wound healing receiving growth factor (36/56 (64.28%) versus 7/27 (25.92%); RR 2.45, 95% CI 1.27 to 4.74, I<sup>2</sup> = 0%) (<a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>). Meta‐analysis of five trials showed that recombinant human platelet‐derived growth factor (becaplermin) increased the proportion of the participants with complete wound healing compared with placebo (205/428 (47.89%) versus 109/335 (32.53%); RR 1.47, 95% CI 1.23 to 1.76, I<sup>2</sup> = 74%) (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). Meta‐analysis of two trials comparing recombinant human basic fibroblast growth factor versus placebo or no growth factor showed inconclusive results regarding proportion of participants with complete wound healing (60/106 (56.60%) versus 27/59 (45.76%); RR 1.23, 95% CI 0.88 to 1.72, I<sup>2</sup> = 62% P value 0.22) (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). One trial comparing recombinant human epidermal growth factor versus placebo showed an increase in the incidence of complete wound healing using growth factor (25/29 (86.28%) versus 14/28 (50%); RR 1.72, 95% CI 1.16 to 2.57) (<a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>). One trial comparing recombinant human vascular endothelial growth factor versus placebo showed no clear evidence of a difference regarding complete wound closure (15/29 (51.72%) versus 9/26 (34.61%); RR 1.49, 95% CI 0.79 to 2.82; P value 0.21) (<a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>). The subgroup test showed no significant difference between the two groups (I<sup>2</sup> = 0%, P value 0.55). However, the quality of the evidence showed in this subgroup analysis should be considered either low or very low. It is due to severe imprecision (wide confidence intervals) based on small sample size and low number of event (complete wound closure), inconsistency and limitations of design and execution of these trials. See <a href="./references#CD008548-fig-0010" title="">Analysis 3.1</a>. </p> </section> <section id="CD008548-sec-0080"> <p><b>Sensitivity analysis taking attrition into consideration</b></p> <p>Eight of the 12 trials combined for this outcome reported the exact number of participants with missing data in the intervention and the control groups. These trials involved 1043 participants (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). </p> </section> <section id="CD008548-sec-0081"> <p><b>'Best‐worst case' scenario</b></p> <p>In a best‐worst case scenario analysis where none of the drop‐outs/participants were lost from the experimental arm, but all of the drop‐outs/participants lost from the control arm experienced the outcome, including all randomised participants in the denominator, meta‐analysis of eight trials showed a higher likelihood of complete wound healing in the participants receiving any growth factor compared with those exposed to placebo or no growth factor (417/607 (68.69%) versus 142/436 (32.56%); RR 2.09, 95% CI 1.81 to 2.41; I<sup>2</sup> = 57%; P value 0.00001). </p> </section> <section id="CD008548-sec-0082"> <p><b>'Worst‐best case' scenario</b></p> <p>In a worst‐best case scenario analysis (all drop‐outs/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomised participants in the denominator) we did not find clear evidence of a difference in the proportion of participants assigned to any growth factor with complete wound healing compared with placebo or no growth factor (318/607 (52.38%) versus 218/436 (50%); RR 1.05, 95% CI 0.93 to 1.19; I<sup>2</sup> = 60%; P value 0.43). </p> <p>A test for subgroup differences showed a significant difference (I² = 98.2%; P value 0.0001). See <a href="./references#CD008548-fig-0011" title="">Analysis 4.1</a>. </p> </section> </section> <section id="CD008548-sec-0083"> <h6 class="title">Individual growth factor versus active control</h6> <p>There is inconclusive evidence of a difference between autologous growth factor and oxidized regenerate cellulose/collagen biomaterial regarding complete wound healing (4/34 (11.76%) versus 2/17 (11.76%); RR 1.00, 95% CI 0.20 to 14.93; P value 1.00) (<a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>). One trial reported inconclusive effects when recombinant human platelet‐derived growth factor (becaplermin) was compared with OASIS Wound Matrix for achieving complete wound healing (10/36 (27.77%) versus 18/37 (48.64%); RR 0.57, 95% CI 0.31 to 1.06; P value 0.08) (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>). There is not conclusive results when recombinant human epidermal growth factor was compared with silver sulphadiazine for reaching complete wound healing (7/30 (23.33%) versus 2/20 (10%); RR 2.33, 95% CI 0.54 to 10.11; P value 0.26) (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>). There was a higher proportion of complete wound healing in participants allocated to recombinant human epidermal growth factor than those receiving actovegin (32/42 (76.19%) versus 8/19 (42.10%); RR 1.81, 95% CI 1.04 to 3.15; P value 0.04) (<a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>). </p> </section> </section> <section id="CD008548-sec-0084"> <h5 class="title">Lower limb amputation (minimum of one toe)</h5> <p>No trials described the extent of the amputation (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>). </p> <p><b>Any growth factor versus placebo or no growth factor</b> </p> <p>Meta‐analysis of two trials showed no clear difference in number of lower limb amputations for growth factors, considered as a group, compared with placebo or no growth factor (19/150 (12.66%) versus 12/69 (17.39%); RR fixed‐effects model 0.74, 95% CI 0.39 to 1.39; I<sup>2</sup> = 0%; P value 0.34, <i>low quality evidence due to limitation in design, execution or both, and imprecision</i>) (<a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>). See <a href="./references#CD008548-fig-0006" title="">Analysis 1.2</a>. </p> <p><b>Individual growth factor versus active control</b> </p> <p>One trial comparing recombinant human epidermal growth factor versus actovegin showed no clear evidence of a difference regarding the incidence of lower limb amputation (2/42 (4.76%) versus 2/19 (10.52%); RR 0.45, 95% CI 0.07 to 2.98; P value 0.41) (<a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>). Meta‐analysis of two trials comparing two doses of recombinant human epidermal growth factor, 75 μg and 25 μg, showed no clear difference regarding lower limb amputation (15/76 (19.73%) versus 16/66 (24.24%); RR 0.82, 95% CI 0.44 to 1.52; I<sup>2</sup> = 0%; P value 0.52) (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>). </p> </section> <section id="CD008548-sec-0085"> <h5 class="title">Time to complete healing of the diabetic foot ulcer</h5> <p>Fifteen trials assessed time to complete healing of the diabetic foot ulcer. However, no trial reported hazard ratios or information that would allow us to calculate it. Most trials did not state explicitly that all participants achieved complete healing (<a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>; <a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0006" title="DriverVR . A prospective, randomized, controlled, blinded, multicenter pivotal trial of a platelet rich plasma gel versus control when added to the standard of care in the treatment of non‐healing diabetic foot ulcers. Diabetes2006;55(Suppl 1):A25. DriverVR , HanftJ , FyllingCP , BeriouJM , AutoGel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet‐rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management2006;52(6):68‐87. ">Driver 2006</a>; <a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>; <a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>; <a href="./references#CD008548-bbs2-0018" title="RobsonMC , SteedDL , McPhersonJM , PrattBM . Effects of transforming growth factor +ƒ2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose‐ranging trial. Journal of Applied Research2002;2:133‐45. ">Robson 2002</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>; <a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>), see <a href="./appendices#CD008548-sec-0118">Appendix 10</a> for details. </p> </section> </section> <section id="CD008548-sec-0086"> <h4 class="title">Secondary outcomes</h4> <section id="CD008548-sec-0087"> <h5 class="title">Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)</h5> <p>One trial comparing recombinant human vascular endothelial growth factor (29 participants) versus placebo (26 participants) showed inconclusive difference in terms of ulcers‐free days following treatment (HR 0.64, 95% CI 0.14 to 2.94 P value 0.56) (<a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>). </p> </section> <section id="CD008548-sec-0088"> <h5 class="title">Quality of life</h5> <p>None of the included trials addressed quality of life.</p> </section> <section id="CD008548-sec-0089"> <h5 class="title">Adverse events</h5> <section id="CD008548-sec-0090"> <h6 class="title">Any growth factor versus placebo or no growth factor</h6> <p>Meta‐analysis of four trials reporting number of participants with events showed no clear evidence of a difference between all growth factors when considered as a group compared with placebo or no growth factor in terms of adverse events (non‐serious and serious) (109/232 (46.98%) versus 63/153 (41.17%); RR 0.98, 95% CI 0.79 to 1.22; I<sup>2</sup> = 0%; P value 0.85, <i>low quality evidence</i>) (<a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>; <a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>; <a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>). See <a href="./references#CD008548-fig-0008" title="">Analysis 1.4</a>. </p> <p><b>Individual growth factor versus placebo or no growth factor</b> </p> <p>One trial comparing arginine‐glycine‐aspartic acid peptide matrix with placebo reported adverse events as follows: "0.65 events per patient (N = 26) in arginine‐glycine‐aspartic acid peptide matrix compared with 1.16 (N = 29) in the placebo group" (<a href="./references#CD008548-bbs2-0022" title="SteedD , RicottaJJ , PrendergastJJ , KaplanRJ , WebsterMW , McGillJB , et al. Promotion and acceleration of diabetic ulcer healing by arginine glycine‐aspartic acid (RGD) peptide matrix. Diabetes Care1995;18:39–46. ">Steed 1995b</a>). One trial showed no clear difference in overall adverse events when recombinant human platelet‐derived growth factor (becaplermin) was compared with placebo (31/61 (50.81%) versus 34/57 (59.64%); RR 0.85, 95% CI 0.61 to 1.18; P value 0.34) (<a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>). </p> <p>One trial comparing recombinant human platelet‐derived growth factor versus placebo reported an incidence of serious adverse events similar across comparison groups (25%, 30% and 24% either recombinant human platelet‐derived growth factor 30 μg/g or 100 μg/g, and placebo, respectively (<a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). </p> <p>Meta‐analysis of two trials comparing recombinant human platelet‐derived growth factor (becaplermin) with placebo showed no clear difference between treatment groups in terms of: infection (35/95 (36.84%) versus 28/127 (22.04%); RR 1.57, 95% CI 0.37 to 6.71, I<sup>2</sup> = 88%; P value 0.54); cellulitis (11/165 (6.66%) versus 17/127 (13.38%); RR 0.49, 95% CI 0.24 to 1.02, I<sup>2</sup> = 0%; P value 0.06); peripheral oedema (9/165 (5.45%) versus 16/127 (12.59%); RR 0.44, 95% CI 0.20 to 0.96, I<sup>2</sup> = 0%; P value 0.04); pain (17/165 (10.30%) versus 16/125 (12.8%); RR 0.78, 95% CI 0.41 to 1.49, I<sup>2</sup> = 0%; P value 0.45); or skin ulceration (14/165 (8.48%) versus 10/127 (7.87%); RR 1.08, 95% CI 0.49 to 2.37, I<sup>2</sup> = 0%; P value 0.85) (<a href="./references#CD008548-bbs2-0005" title="d'HemecourtPA , SmeillJM , HugillJV , PrigoffMM . The effect of topically applied sodium carboxymethylcellulose gel in nonhealing, lower extremity ulcers in patients with diabetes. European Tissue Repair Society. Koln, Germany, 23‐27 August 1997:Abstracts. d'HemecourtPA , SmiellJM , KarimMR . Sodium carboxymethyl cellulose aqueous‐based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds1998;10(3):69‐75. ">d'Hemecourt 1998</a>; <a href="./references#CD008548-bbs2-0021" title="SteedDL . Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity ulcers. Plastic and Reconstructive Surgery2006;117 (Suppl7):143‐9. SteedDL , WebsterMW , RicottaJJ , LutermanA , BrownS , ComerotaAJ , et al. Clinical evaluation of recombinant human platelet‐derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery1995;21:71‐81. ">Steed 1995a</a>). See <a href="./references#CD008548-fig-0015" title="">Analysis 6.2</a> to <a href="./references#CD008548-fig-0019" title="">Analysis 6.6</a>. </p> <p>Meta‐analysis of two trials comparing recombinant human basic fibroblast growth factor with placebo did not find a difference in terms of infection (3/106 (2.83%) versus 3/59 (5.08%); RR 0.77, 95% CI 0.18 to 3.29; I<sup>2</sup> = 0%; P value 0.72) (<a href="./references#CD008548-bbs2-0017" title="RichardJL , Parer‐RichardC , DauresJP , ClouetS , VannereauD , BringerJ , et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: A pilot, randomized, double‐blind, placebo‐controlled study. Diabetes Care1995;18:64‐9. ">Richard 1995</a>; <a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). <a href="./references#CD008548-fig-0021" title="">Analysis 7.2</a>. </p> <p>One trial showed no clear evidence of a difference between recombinant human basic fibroblast growth factor versus placebo in terms of adverse events (4/97 (4.12%) versus 3/51 (5.88%); RR 0.26, 95% CI 0.02 to 2.83; P value 0.27) (<a href="./references#CD008548-bbs2-0026" title="UchiH , IgarashiA , UrabeK , KogaT , NakayamaJ , KawamoriR , et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. European Journal of Dermatology2009;19:461‐8. ">Uchi 2009</a>). One trial showed no clear difference between recombinant human epidermal growth factor group and placebo in terms of any adverse event (65/101 (64.35%) versus 31/48 (64.58%); RR 1.00, 95% CI 0.77 to 1.29; P value 0.98), or any severe adverse event (8/101 (7.92%) versus 2/48 (4.16%); RR 1.90, 95% CI 0.42 to 8.61; P value 0.40) (<a href="./references#CD008548-bbs2-0008" title="Fernández‐MontequínJI , BetancourtBY , Leyva‐GonzalezG , MolaEL , Galán‐NaranjoK , Ramírez‐NavasM , et al. Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure. International Wound Journal2009;6:67‐72. Fernández‐MontequínJI , Valenzuela‐SilvaCM , DíazOG , SavigneW , Sancho‐SouteloN , Rivero‐FernándezF , Cuban Diabetic Foot Study Group. Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study. International Wound Journal2009;6:432‐43. ">Fernández‐Montequin 2009</a>). One trial comparing recombinant human vascular endothelial growth factor with placebo showed inconclusive results in the incidence of adverse events during the six‐week treatment period (14/29 (48.27%) versus 13/26 (50%); RR 0.97, 95% CI 0.56 to 1.65; P value 0.90) or the 12‐week observation period (5/26 (19.23%) versus (6/23 (26.08%); RR 0.74, 95% CI 0.26 to 2.10; P value 0.57). This trial also did not show a conclusive difference in terms of serious adverse events during the six‐week treatment period (2/29 (6.89%) versus 3/26 (11.53%); RR 0.60, 95% CI 0.11 to 3.30; P value 0.56) or 12‐week observation period (3/26 (11.53%) versus 3/26 (11.53%); RR 1.00, 95% CI 0.22 to 4.50; P value 1.00) (<a href="./references#CD008548-bbs2-0009" title="HanftJR , PollakRA , BarbulA , vanGilsC , KwonPS , GraySM , et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care2008;17:30‐2, 34‐7. KwonP , BreenTJ , GrayS , LynchCJ , SembaCP , HanftJR , et al. Results of a phase I, randomized, double‐blind, placebo‐controlled trial of topical rhVEGF (telbermin) for the treatment of diabetic foot ulcers. Wound Management2006;54:102. ">Hanft 2008</a>). </p> <p><b>Individual growth factor versus active control</b> </p> <p>One trial comparing recombinant human platelet‐derived growth factor (becaplermin) with OASIS Wound Matrix did not find clear evidence of a difference in terms of treatment related events (10/36 (27.77%) versus 17/37 (45.94%); RR 0.60, 95% CI 0.32 to 1.14; P value 0.12) (<a href="./references#CD008548-bbs2-0016" title="NiezgodaJA , VanGilsCC , FrykbergRG , HoddeJP . Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Advances in Skin and Wound Care2005;18:258‐66. ">Niezgoda 2005</a>). One trial comparing different doses of recombinant human epidermal growth factor, 75 μg versus 25 μg, showed no difference in terms of burning sensation (5/23 (21.73%) versus 2/18 (11.11%); RR 1.96, 95% CI 0.43 to 8.94 P value 0.39; 41 participants), or local pain (4/23 (17.39%) versus 3/18 (16.66%); RR 1.04, 95% CI 0.27 to 4.08; P value 0.95; 41 participants) (<a href="./references#CD008548-bbs2-0007" title="Fernández‐MontequinJI , Infante‐CristiaE , Valenzuela‐SilvaC , Franco‐PerezN , Savigne‐GutierrezW , Artaza‐SanzH , et al. Intralesional injections of Citoprot‐P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal2007;4:333‐43. ">Fernández‐Montequin 2007</a>). One trial showed evidence of a difference in reduction of local wound pain in participants who received recombinant human acidic fibroblast growth factor compared with those who received recombinant human basic fibroblast growth factor (2/104 (1.92%) versus 6/35 (17.14%); RR 0.11, 95% CI 0.02 to 0.53; 9 P value 0.006) (<a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008548-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008548-sec-0091">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008548-sec-0149">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008548-sec-0091"></div> <section id="CD008548-sec-0092"> <h3 class="title" id="CD008548-sec-0092">Summary of main results</h3> <p>This Cochrane systematic review of growth factors for treating foot ulcers in people with diabetes included 28 randomised clinical trials that incorporated 2365 participants. Trials evaluated 11 different experimental growth factors compared with several different control interventions. Overall, the trials had a high risk of bias and were underpowered. Most of the trials, 82% (23/28), did not report an <i>a priori</i> sample size estimation. Drug companies sponsored at least 14 of the trials. The trials were conducted in 10 countries (Canada, China, Cuba, France, Greece, India, Iran, Italy, Japan, and the USA). In general the trials were conducted in the out‐patient (ambulatory) setting. The reporting of trial participants characteristics was ill‐defined with regard to their type of diabetes mellitus and etiology of their diabetic foot ulcer. </p> <p>Meta‐analysis was possible only on six types of experimental growth factors: platelet‐derived growth factor, autologous growth factor; platelet‐derived wound healing formula, recombinant human platelet‐derived growth factor, recombinant human basic fibroblast growth factor, and human epidermal growth factor. </p> <p>We were able to meta‐analyse data on trial participants with complete wound healing. Meta‐analysis of 12 trials showed that all growth factors, when considered as a group, seemed to increase the proportion of participants with complete wound healing significantly compared with placebo or no growth factor. The quality of the estimate was qualified as low due to limitations in design and execution of included trials, and inconsistency (<a href="./full#CD008548-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>We were able to meta‐analyse data on lower limb amputation (minimum of one toe). One meta‐analysis of two trials showed no clear evidence that growth factors, when as considered as a group, reduced the risk of lower limb amputation compared with placebo or no growth factor. Evidence was downgraded to very low due to pitfalls in design and execution of included trials, and a very small sample size and very low number of events (<a href="./full#CD008548-tbl-0001">summary of findings Table for the main comparison</a>). Another meta‐analysis of two trials that compared two doses of recombinant human epidermal growth factor, 75 μg and 25 μg, did not show a significant difference between the two doses. </p> <p>Eleven trials reported time to complete healing of the diabetic foot ulcer, however, meta‐analysis was not possible due to the unique comparisons within each trial, failure to report data, with or without a high rate of withdrawals. One trial comparing recombinant human vascular endothelial growth factor versus placebo showed inconclusive result on ulcer‐free days following treatment. Trials did not report data on quality of life. Growth factors compared against placebo or no growth factor showed no difference in terms of any adverse event. However, overall, safety data were poorly reported and adverse events may have been underestimated. Evidence was considered as low due to limitations in design and execution, and low number of event (<a href="./full#CD008548-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Trials with a 20‐week or longer follow‐up seemed to be more effective in increasing the number of participants with complete wound closure than trials with a follow‐up of less than 20 weeks. However, there was no an conclusive difference between these groups. </p> <p>We conducted a subgroup analysis of trials by type of growth factor. There was an inconclusive difference between growth factor versus placebo or no growth factor in terms of the number of participants with complete wound closure. This is could be due to small sample size and low number of events. </p> <p>In terms of complete wound closure we found a clear difference between the 'best‐worse case' scenario and the 'worst‐best case' scenario in sensitivity analyses that took attrition into consideration. It should be interpreted as inconsistency due to missing data. </p> </section> <section id="CD008548-sec-0093"> <h3 class="title" id="CD008548-sec-0093">Overall completeness and applicability of evidence</h3> <p>This Cochrane review found evidence suggesting that growth factors might be useful for increasing complete wound closure of foot ulcers in people with diabetes , though this conclusion is based on randomised clinical trials with a high risk of bias due to pitfalls in design and execution of the included trials. Therefore, and based on GRADE findings, future research are a need to know with a better certainty the clinical benefits of growth factors for treating diabetic foot ulcers. Furthermore, the safety profile of all the growth factors is unclear. </p> <p>The results in this review are based on data from trials that included a broad range of participants with different co‐morbidities, who received different treatment approaches. That heterogeneity downgraded the quality of evidence. We cannot rule out that the calculations of the potential effects have been overestimated due to poor methodological quality (bias risks, design, analysis and the small information size. Therefore, these three variables, i.e., high heterogeneity, pitfalls in methodology, and small sample size and low number of events, even after meta‐analysis, depleted the quality of evidence. Futhermore, we cannot exclude an underestimation of harms. A caveat concerning the safety of recombinant human platelet‐derived growth factor (becaplermin) has been outlined recently; this relates to the risk of cancer in people who use three tubes or more compared to that in non‐users (<a href="./references#CD008548-bbs2-0075" title="Food , DrugAdministration . Regranex (becaplermin) Gel. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094968.htm (accessed 6 July 2011). ">FDA 2008</a>; <a href="./references#CD008548-bbs2-0135" title="PapanasN , MaltezosE . Benefit‐risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Safety2010;33(6):455‐61. ">Papanas 2010</a>). However, an observational study reported that this growth factor does not appear to increase the risk of cancer or cancer mortality (<a href="./references#CD008548-bbs2-0176" title="ZiyadehN , FifeD , WalkerAM , WilkinsonGS , SeegerJD . A matched cohort study of the risk of cancer in users of becaplermin. Advances in Skin and Wound Care2011;24(1):31‐9. ">Ziyadeh 2011</a>), though further high‐quality data are clearly needed. </p> </section> <section id="CD008548-sec-0094"> <h3 class="title" id="CD008548-sec-0094">Quality of the evidence</h3> <p>GRADE assessments were conducted on outcomes of both meta‐analysis and non‐pooled trials. None of the trials was graded as providing strong evidence, primarily because of small sample sizes (even after meta‐analysis) which generate wide confidence intervals with low precision of estimate of the intervention effects, and the high risk of bias due to a lack of adequate randomisation methods, lack of blinding, high attrition, and unclear reporting of outcomes. </p> <p>Quality of evidence also had to be downgraded due to inconsistency. We can't reject a potential detection bias ‐wound healing is a fairly subjective outcome‐ where is there is no blinded outcome assessment or unclear for this, even though due to clear definition of complete wound closure. </p> <p>See <a href="./full#CD008548-tbl-0001">summary of findings Table for the main comparison</a> for complete assessment and rationale for ratings. </p> <p>This review assessed the impact of missing data on the effect of intervention in increasing the proportion of participants with complete wound closure (<a href="./references#CD008548-fig-0011" title="">Analysis 4.1</a>) using best/worst and /best case scenarios. If the amount of missing data is large, the conclusion on the difference between the comparison groups is not valid (<a href="./references#CD008548-bbs2-0098" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7211):670‐4. ">Hollis 1999</a>). This Cochrane review found a significant subgroup difference comparing all trials, best/worst and /best case scenarios (<a href="./references#CD008548-fig-0011" title="">Analysis 4.1</a>). </p> <p>This Cochrane review has identified the following issues that should be considered when planning future trials: inconsistent information concerning the healing percentage of wound closure definition provided by trial reports, differences in definitions of outcomes, and inconsistency of reported outcomes need to be avoided. Trials should adopt an agreed set of core outcomes for each medical condition (<a href="./references#CD008548-bbs2-0071" title="ClarkeM . Standardising outcomes for clinical trials and systematic reviews. Trials2007;8:39. ">Clarke 2007</a>). This approach may reduce the impact of outcome reporting bias (<a href="./references#CD008548-bbs2-0112" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). </p> <p>The impact of outcome reporting bias may be reduced by adopting the recommendations of <i>The Patient‐Centered Outcomes Research Institute</i> (PCORI) (<a href="./references#CD008548-bbs2-0136" title="Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: 'Our questions, our decisions: Standards for patient‐centered outcomes research'. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 2 August 2012). ">PCORI 2012</a>). This organisation was established by United States Congress as an independent, non‐profit organisation, created to conduct research to provide information about the best available evidence to help patients and their healthcare providers make more informed decisions. PCORI’s research is intended to give patients a better understanding of the prevention, treatment and care options available, and the science that supports those options (<a href="./references#CD008548-bbs2-0078" title="GabrielSE , NormandSL . Getting the methods right ‐ the foundation of patient‐centered outcomes research. The New England Journal of Medicine2012;367(9):787‐90. ">Gabriel 2012</a>; <a href="./references#CD008548-bbs2-0060" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636‐40. ">Basch 2012</a>; <a href="./references#CD008548-bbs2-0136" title="Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: 'Our questions, our decisions: Standards for patient‐centered outcomes research'. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 2 August 2012). ">PCORI 2012</a>; <a href="./references#CD008548-bbs2-0152" title="SelbyJV , BealAC , FrankL . The Patient‐Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA2012;307(15):1583‐4. ">Selby 2012</a>). </p> </section> <section id="CD008548-sec-0095"> <h3 class="title" id="CD008548-sec-0095">Potential biases in the review process</h3> <p>There is a group of biases called significance‐chasing biases (<a href="./references#CD008548-bbs2-0104" title="IoannidisJP . Meta‐research: the art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>), which includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias. Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, this Cochrane review has a low risk of publication bias due to the meticulous trial search that was performed, and the fact that we emailed the main authors of a number of the trials identified. Selective outcome reporting bias operates through suppression of information about specific outcomes and has similarities to publication bias of whole studies or trials, in that ‘negative’ results remain unpublished (<a href="./references#CD008548-bbs2-0104" title="IoannidisJP . Meta‐research: the art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). We were surprised to find how few times amputations or mortality were reported in the trials. This Cochrane review found that 75% of the included randomised clinical trials had high risks of selective outcome reporting. For example, adverse events were not reported (<a href="./references#CD008548-bbs2-0001" title="AfshariM , LarijaniB , FadayeeM , GhaharyA , PajouhiM , BastanhaghM , et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy2005;2:759‐65. ">Afshari 2005</a>; <a href="./references#CD008548-bbs2-0003" title="BhansaliA , VenkateshS , DuttaP , DhillonMS , DasS , AgrawalA . Which is the better option: recombinant human PDGF‐BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off‐loaded by a customized contact cast?. Diabetes Research and Clinical Practice2009;83(1):e13‐6. ">Bhansali 2009</a>; <a href="./references#CD008548-bbs2-0004" title="ChenA , LongXH , HuangC . Analysis of the effect of recombined human epidermal growth factor derivate applied externally in treating diabetic foot. Modern Nursing2004;10(3):274‐5. ">Chen 2004</a>, <a href="./references#CD008548-bbs2-0012" title="JaiswalSS , GambhirRPS , HarishAA . Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian Journal of Surgery2010;72:31‐5. ">Jaiswal 2010</a>; <a href="./references#CD008548-bbs2-0013" title="KakagiaDD , KazakosKJ , XarchasKC , KaranikasM , GeorgiadisGS , TripsiannisG , et al. Synergistic action of protease‐modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and its Complications2007;21:387‐91. ">Kakagia 2007</a>; <a href="./references#CD008548-bbs2-0014" title="LandsmanA , AgnewP , ParishL , JosephR , GalianoRD . Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture‐controlling smart dressing: a randomized, multicenter, prospective analysis. Journal of the American Podiatric Medical Association2010;100(3):155‐60. ParishL , RouthH , ParishJ . Diabetic foot ulcers: a randomized multicenter study comparing a moisture‐controlling dressing with a topical growth factor. Journal of the American Academy of Dermatology2009;60(Suppl):AB202. ">Landsman 2010</a>; <a href="./references#CD008548-bbs2-0019" title="SaldalamacchiaG , LapiceE , CuomoV , DeFeoE , D'AgostinoE , RivelleseAA , et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutrition Metabolism and Cardiovascular Diseases2004;14:395‐6. SaldalamacchiaG , LapiceE , CuomoV , DeFeoME , D'AgostinoE , RivelleseAA , et al. Use of autologous platelet gel for the treatment of diabetic foot ulcers. Giornale Italiano di Diabetologia e Metabolismo2004;24:103‐5. ">Saldalamacchia 2004</a>; <a href="./references#CD008548-bbs2-0020" title="SteedD , GoslenJB , HollowayGA , MaloneJM , BuntTJ , WebsterMW . Randomised prospective double blind trial in healing chronic diabetic foot ulcers: CT‐102 activated platelet supernatant, topical versus placebo. Diabetes Care1992;15:1598–604. ">Steed 1992</a>; <a href="./references#CD008548-bbs2-0023" title="SteedDL , EdingtonHD , WebsterMW . Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. Wound Repair and Regeneration1996;4:230‐3. ">Steed 1996</a>; <a href="./references#CD008548-bbs2-0024" title="TanY , XiaoJ , HuangZ , XiaoY , LinS , JinL , et al. Comparison of the therapeutic effects of recombinant human acidic and basic fibroblast growth factors in wound healing in diabetic patients. Journal of Health Science2008;54:432‐40. ">Tan 2008</a>; <a href="./references#CD008548-bbs2-0025" title="TsangMW , WongWK , HungCS , LaiKM , TangW , CheungEY , et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856‐61. ">Tsang 2003</a>), or were poorly reported in a total of 16 trials (<a href="./references#CD008548-bbs2-0010" title="HardikarJV , ReddyYC , BungDD , VarmaN , ShilotriPP , PrasadED , et al. Efficacy of recombinant human platelet‐derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double‐blind, placebo‐controlled study in India. Wounds2005;17:141‐52. ">Hardikar 2005</a>; <a href="./references#CD008548-bbs2-0011" title="HollowayGA , SteedDL , DeMarcoMJ , MatsumotoT , MoosaHH , WebsterMW , et al. A randomised controlled dose response trial of activated platelet supernatant, topical CT‐102 in chronic, non healing diabetic wounds. Wounds1993;5:198–206. ">Holloway 1993</a>; <a href="./references#CD008548-bbs2-0015" title="LyonsTE , MillerMS , SerenaT , SheehanP , LaveryL , KirsnerRS , et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. American Journal of Surgery2007;193(1):49‐54. ">Lyons 2007</a>; <a href="./references#CD008548-bbs2-0167" title="ViswanathanV , PendseyS . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN‐DTM 150) in healing diabetic foot ulcers. Wounds2006;18:186‐96. ">Viswanathan 2006</a>; <a href="./references#CD008548-bbs2-0028" title="WiemanTJ , SmiellJM , SuY . Efficacy and safety of a topical gel formulation of recombinant human platelet‐derived growth factor‐BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo‐controlled double‐blind study. Diabetes Care1998;21(5):822‐7. ">Wieman 1998a</a>). These 16 trials incorporated 55% of the randomised participants (1289/2365) included in this review. This review found no evidence of asymmetry of the funnel plot for complete wound closure (<a href="#CD008548-fig-0004">Figure 4</a>). </p> </section> <section id="CD008548-sec-0096"> <h3 class="title" id="CD008548-sec-0096">Agreements and disagreements with other studies or reviews</h3> <p>The results of our review are similar to the findings from other systematic reviews (<a href="./references#CD008548-bbs2-0067" title="BuchbergerB , FollmannM , FreyerD , HuppertzH , EhmA , WasemJ . The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers. GMS Health Technology Assessment2010;6:Doc12. ">Buchberger 2010</a>; <a href="./references#CD008548-bbs2-0131" title="O'MearaS , CullumN , MajidM , SheldonT . Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technology Assessment2000;4(21):1‐237. ">O'Meara 2000</a>) and a narrative review of complete closure of diabetic foot ulcer using growth factors (<a href="./references#CD008548-bbs2-0170" title="WiemanTJ . Clinical efficacy of becaplermin (rhPDGF‐BB) gel. Becaplermin Gel Studies Group. American Journal of Surgery1998;176(2A Suppl):74S‐9S. [PUBMED: 9777976] ">Wieman 1998b</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008548-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008548-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008548-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008548-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure.P‐value (two tailed) for Egger's test = 0.43" data-id="CD008548-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for comparison effect of any growth factor versus placebo or no growth factor on 100% complete wound closure. </p> <p>P‐value (two tailed) for Egger's test = 0.43</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure." data-id="CD008548-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe)." data-id="CD008548-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)." data-id="CD008548-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious)." data-id="CD008548-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Any growth factor versus placebo or no growth factor, Outcome 4 Adverse events (non‐serious and serious). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure." data-id="CD008548-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks), Outcome 1 Participants with complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure." data-id="CD008548-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor), Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure." data-id="CD008548-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition), Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure." data-id="CD008548-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe)." data-id="CD008548-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Platelet derived wound healing formula (PDWHF) versus control, Outcome 2 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure." data-id="CD008548-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection." data-id="CD008548-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis." data-id="CD008548-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 3 Adverse event: cellulitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema." data-id="CD008548-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 4 Adverse event: peripheral oedema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain." data-id="CD008548-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 5 Adverse event: pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration." data-id="CD008548-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo, Outcome 6 Adverse event: skin ulceration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure." data-id="CD008548-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 1 Complete wound closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection." data-id="CD008548-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo, Outcome 2 Adverse event: infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008548-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/urn:x-wiley:14651858:media:CD008548:CD008548-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_t/tCD008548-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe)." data-id="CD008548-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Recombinant human epidermal growth factor versus active control, Outcome 1 Lower limb amputation (minimum of one toe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/media/CDSR/CD008548/image_n/nCD008548-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008548-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> foot ulcers in people with diabetes<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> any growth factor<br/> <b>Comparison:</b> placebo or no growth factor </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Any growth factor</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete wound closure</b> <br/> Follow‐up: 4 to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>523 per 1000</b> <br/> (454 to 599) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.51</b> <br/> (1.31 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1316<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.‐ Growth factors investigated included autologous growth factor (1 trial); platelet‐derived wound healing formula (2 trials); recombinant human platelet‐derived growth factor (becaplermin) (5 trials), recombinant human basic fibroblast growth factor (2 trials), recombinant human epidermal growth factor (1 trial), and transforming growth factor (1 trial). </p> <p>2.‐ Trials differed in quality.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower limb amputation (minimum of one toe)</b> <br/> Follow‐up: 8 to 20 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> <br/> (64 to 235) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.39 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelet‐derived wound healing formula (1 trial), and recombinant human epidermal growth factor (1 trial) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial authors reported recurrence of ulcer in 27% (4/15) of participants receiving growth factor (recombinant human vascular endothelial growth factor) versus 33% (3/9) in placebo group. Hazard ratio was calculated using data transformation. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete healing of the diabetic foot ulcer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not possible due to the unique comparisons within each trial, failure to report data, with or without a high rate of withdrawals. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials assessed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (non‐serious and serious)</b> <br/> Follow‐up: 5 to 20 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>404 per 1000</b> <br/> (325 to 502) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.79 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recombinant human epidermal growth factor (1 trial), recombinant human platelet‐derived growth factor (1 trial), recombinant human vascular endothelial growth factor (1 trial), thrombin‐induced, platelet‐released platelet‐derived wound healing formula (1 trial). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk is based on the risks for the control group in the meta‐analysis.<br/> <sup>2</sup> Downgraded one level for limitations in design and execution: Eleven out thirteen trials assessing this outcome have high risk for selection bias. And outcome assessment was performed in unclear fashion.<br/> <sup>3</sup> Downgraded one level for inconsistency (I<sup>2</sup>: 51%).<br/> <sup>4</sup> Downgraded one level for limitations in design and execution.<br/> <sup>5</sup> Downgraded two levels for imprecision: small sample size and very low rate of events conducting to wide confidence intervals.<br/> <sup>6</sup> Downgraded one level for imprecision: Low rate of adverse events resulting in wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any growth factor compared with placebo or no growth factor for diabetic foot ulcer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/full#CD008548-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any growth factor versus placebo or no growth factor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.39, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.14, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events (non‐serious and serious) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any growth factor versus placebo or no growth factor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials with length of follow‐up &lt; 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.00, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials with length of follow up ≥ 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.38, 1.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis of trials with follow‐up &lt; 20 weeks versus follow‐up ≥ 20 weeks)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.30, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Autologous growth factor (AGF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.23, 17.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platelet‐derived wound‐healing formula (PDWHF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Recombinant human platelet‐derived growth factor (rHuPDGF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.23, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Recombinant human basic fibroblast growth factor (rHubFBGF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.88, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Recombinant human epidermal growth factor (rHuEGF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.16, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Recombinant human vascular endothelial growth factor (rHuVEGF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.79, 2.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (subgroup analysis by type of growth factor)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 All trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.31, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Best‐worst case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.79, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Worst‐best case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Any growth factor versus placebo or no growth factor (sensitivity analyses considering attrition)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platelet derived wound healing formula (PDWHF) versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.27, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [0.11, 43.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platelet derived wound healing formula (PDWHF) versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.21, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.41, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse event: cellulitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.23, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse event: peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse event: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse event: skin ulceration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.49, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Recombinant human platelet‐derived growth factor (rHuPDGF) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complete wound closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse event: infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Recombinant human basic fibroblast growth factor (rHubFBGF) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008548-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Recombinant human epidermal growth factor versus active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Lower limb amputation (minimum of one toe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Recombinant human epidermal growth factor versus actovegin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.07, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Recombinant human epidermal growth factor 75 μg dose versus 25 μg dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.43, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Recombinant human epidermal growth factor versus active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008548.pub2/references#CD008548-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008548.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008548-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008548-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008548-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008548-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008548-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD008548-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008548\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008548\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008548.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008548.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008548.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008548.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716119757"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716119760"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008548.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d97bbdc22f409',t:'MTc0MDcxNjEyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 